

# CITATION REPORT

List of articles citing

Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group

DOI: 10.1186/s40425-017-0300-z  
, 2017, 5, 95.

**Source:** <https://exaly.com/paper-pdf/68493280/citation-report.pdf>

**Version:** 2024-04-20

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
1252	Management of Metastatic Melanoma in 2018. <b>2018</b> , 4, 857-858		22
1251	Multimodality imaging of endocrine immune related adverse events: a primer for radiologists. <b>2018</b> , 50, 96-103		18
1250	Clinical presentation of immune checkpoint inhibitor-induced inflammatory arthritis differs by immunotherapy regimen. <b>2018</b> , 48, 553-557		89
1249	Targeted Therapies and Immunotherapy for Gynecologic Malignancies: Living Longer, Living Better With Noncytotoxic Options in Recurrent Disease. <b>2018</b> , 40, 358-360		1
1248	Focal immune-related pancreatitis occurring after treatment with programmed cell death 1 inhibitors: a distinct form of autoimmune pancreatitis?. <b>2018</b> , 95, 123-126		4
1247	Hepatitis is the new myositis: immune checkpoint inhibitor-induced myositis. <b>2018</b> , 28, 484-485		5
1246	Checkpoint inhibitor-associated autoimmunity. <b>2018</b> , 32, 781-802		9
1245	Reply to D.L. Kimpel et al. <b>2018</b> , 36, 2744		
1244	Kidney Cancer: Toxicity Management, Symptom Control, and Palliative Care. <b>2018</b> , JCO2018790188		2
1243	Where We Stand With Immunotherapy in Colorectal Cancer: Deficient Mismatch Repair, Proficient Mismatch Repair, and Toxicity Management. <b>2018</b> , 38, 239-247		63
1242	Cardio-toxicity of checkpoint inhibitors. <b>2018</b> , 10, S4400-S4404		11
1241	Identifying and managing the adverse effects of immune checkpoint blockade. <b>2018</b> , 10, S480-S489		55
1240	"Comparison of the toxicity profile of PD-1 versus PD-L1 inhibitors in non-small cell lung cancer": is there a substantial difference or not?. <b>2018</b> , 10, S4065-S4068		13
1239	Severe pneumonitis refractory to steroids following anti-PD-1 immunotherapy. <b>2018</b> , 2018,		10
1238	L'arrivée de l'immunothérapie dans le lymphome de Hodgkin. <b>2018</b> , 105 Suppl 1, S50-S58		
1237	Rheumatic immune-related adverse events secondary to anti-programmed death-1 antibodies and preliminary analysis on the impact of corticosteroids on anti-tumour response: A case series. <b>2018</b> , 105, 88-102		37
1236	Interstitial Lung Disease and Pulmonary Fibrosis: A Practical Approach for General Medicine Physicians with Focus on the Medical History. <b>2018</b> , 7,		30

1235	Immune-related adverse events of immune checkpoint inhibitors: a brief review. <b>2018</b> , 25, 342-347	72
1234	Management of immunotherapy toxicities in older adults. <b>2018</b> , 45, 226-231	12
1233	The Role of PD-1 Checkpoint Inhibition in Gynecologic Malignancies. <b>2018</b> , 19, 70	12
1232	Recent updates in cancer immunotherapy: a comprehensive review and perspective of the 2018 China Cancer Immunotherapy Workshop in Beijing. <b>2018</b> , 11, 142	72
1231	Infliximab for treatment-refractory transverse myelitis following immune therapy and radiation. <b>2018</b> , 6, 153	12
1230	Immune-Related Adverse Events: Pneumonitis. <b>2018</b> , 995, 131-149	14
1229	Immune Checkpoint Inhibitors-Induced Colitis. <b>2018</b> , 995, 151-157	16
1228	Immune Checkpoint Inhibitors-Induced Hepatitis. <b>2018</b> , 995, 159-164	21
1227	Outcomes of vedolizumab therapy in patients with immune checkpoint inhibitor-induced colitis: a multi-center study. <b>2018</b> , 6, 142	84
1226	The Balancing Act between Cancer Immunity and Autoimmunity in Response to Immunotherapy. <b>2018</b> , 6, 1445-1452	81
1225	Immune Checkpoint Immunotherapy for Non-Small Cell Lung Cancer: Benefits and Pulmonary Toxicities. <b>2018</b> , 154, 1416-1423	111
1224	Importance of endoscopic and histological evaluation in the management of immune checkpoint inhibitor-induced colitis. <b>2018</b> , 6, 95	90
1223	Thyroid disorders induced by checkpoint inhibitors. <b>2018</b> , 19, 325-333	54
1222	Immune-related adverse events and atypical radiological response with checkpoint inhibitor immunotherapy in an elderly patient with high PD-L1 expressing lung adenocarcinoma. <b>2018</b> , 9, 33043-33049	8
1221	PD1/PDL1 inhibitors for the treatment of advanced urothelial bladder cancer. <b>2018</b> , 11, 5973-5989	59
1220	Knowns and Unknowns: the Safety and Efficacy of Cancer Immunotherapy in Chronic Liver Disease. <b>2018</b> , 17, 153-155	8
1219	A case of interstitial lung disease with alveolar hemorrhage induced by pembrolizumab. <b>2018</b> , 11, 5879-5883	7
1218	Dermatologic Reactions to Novel Immune Checkpoint Inhibitors. <b>2018</b> , 7, 227-238	3

1217	A severe case of neuro-Sjögren's syndrome induced by pembrolizumab. <b>2018</b> , 6, 110	28
1216	Immunotherapy in Gliomas. <b>2018</b> , 34, 501-512	6
1215	Trial Reporting in Immuno-Oncology (TRIO): an American society of clinical oncology-society for immunotherapy of cancer statement. <b>2018</b> , 6, 108	11
1214	Immune-related adverse events are linked with improved progression-free survival in patients receiving anti-PD-1/PD-L1 therapy. <b>2018</b> , 45, 156-163	38
1213	Aging, immune senescence, and immunotherapy: A comprehensive review. <b>2018</b> , 45, 187-200	40
1212	Infliximab associated with faster symptom resolution compared with corticosteroids alone for the management of immune-related enterocolitis. <b>2018</b> , 6, 103	89
1211	Liver toxicity in the era of immune checkpoint inhibitors: A practical approach. <b>2018</b> , 132, 125-129	14
1210	Nivolumab-induced cold agglutinin syndrome successfully treated with rituximab. <b>2018</b> , 2, 1865-1868	13
1209	Immune Checkpoint Inhibitors: Toward New Paradigms in Renal Cell Carcinoma. <b>2018</b> , 78, 1443-1457	41
1208	Management of challenging immune-related gastrointestinal adverse events associated with immune checkpoint inhibitors. <b>2018</b> , 14, 3187-3198	7
1207	A practical guide for the safe implementation of early phase drug development and immunotherapy program in gynecologic oncology practice. <b>2018</b> , 151, 374-380	0
1206	A whole-blood RNA transcript-based gene signature is associated with the development of CTLA-4 blockade-related diarrhea in patients with advanced melanoma treated with the checkpoint inhibitor tremelimumab. <b>2018</b> , 6, 90	17
1205	Clinical Safety of Combined Targeted and L. Therapy in Oncological Patients. <b>2018</b> , 5,	9
1204	Complete Clinical Remission of Stage IV Triple-Negative Breast Cancer Lung Metastasis Administering Low-Dose Immune Checkpoint Blockade in Combination With Hyperthermia and Interleukin-2. <b>2018</b> , 17, 1297-1303	18
1203	Rheumatic immune-related adverse events from cancer immunotherapy. <b>2018</b> , 14, 569-579	97
1202	Erythema Nodosum as the Initial Presentation of Nivolumab-Induced Sarcoidosis-Like Reaction. <b>2018</b> , 22, 627-629	21
1201	Immune Checkpoint Inhibitor Toxicity Review for the Palliative Care Clinician. <b>2018</b> , 56, 460-472	13
1200	Myocarditis Associated with Immune Checkpoint Inhibitors: An Expert Consensus on Data Gaps and a Call to Action. <b>2018</b> , 23, 874-878	64

1199	Clinical Reasoning: A 77-year-old man presenting with episodic expressive aphasia. <b>2018</b> , 90, e1822-e1826	
1198	Collateral Damage: Insulin-Dependent Diabetes Induced With Checkpoint Inhibitors. <b>2018</b> , 67, 1471-1480	241
1197	Immune Checkpoint Inhibitor Toxicity. <b>2018</b> , 20, 72	63
1196	An update on the Society for Immunotherapy of Cancer consensus statement on tumor immunotherapy for the treatment of cutaneous melanoma: version 2.0. <b>2018</b> , 6, 44	39
1195	Monoclonal antibody therapy in cancer: When two is better (and considerably more expensive) than one. <b>2018</b> , 43, 925-930	4
1194	Immune checkpoint blockade therapy for cancer: An overview of FDA-approved immune checkpoint inhibitors. <b>2018</b> , 62, 29-39	496
1193	The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of non-small cell lung cancer (NSCLC). <b>2018</b> , 6, 75	107
1192	A Case of Nivolumab-Induced Bullous Pemphigoid: Review of Dermatologic Toxicity Associated with Programmed Cell Death Protein-1/Programmed Death Ligand-1 Inhibitors and Recommendations for Diagnosis and Management. <b>2018</b> , 23, 1119-1126	54
1191	Management of adverse events related to checkpoint inhibition therapy. <b>2018</b> , 11, 132-137	17
1190	Safety and Efficacy of Re-treating with Immunotherapy after Immune-Related Adverse Events in Patients with NSCLC. <b>2018</b> , 6, 1093-1099	161
1189	Conservative management of nivolumab-induced pericardial effusion: a case report and review of literature. <b>2018</b> , 7, 11	25
1188	Immune-checkpoint inhibitor-induced diarrhea and colitis in patients with advanced malignancies: retrospective review at MD Anderson. <b>2018</b> , 6, 37	107
1187	Management of Immune Checkpoint Inhibitor Toxicities: A Review and Clinical Guideline for Emergency Physicians. <b>2018</b> , 55, 489-502	45
1186	Immune-Related Thyroiditis with Immune Checkpoint Inhibitors. <b>2018</b> , 28, 1243-1251	87
1185	Treatment of Complications from Immune Checkpoint Inhibition in Patients with Lung Cancer. <b>2018</b> , 19, 46	9
1184	Immune checkpoint inhibitor-related myositis and myocarditis in patients with cancer. <b>2018</b> , 91, e985-e994	157
1183	Radiologic predictors of immune checkpoint inhibitor response in advanced head and neck squamous cell carcinoma. <b>2018</b> , 85, 29-34	12
1182	Expert opinion on thyroid complications in immunotherapy. <b>2018</b> , 79, 555-561	21

1181	Cardiovascular safety of oncologic agents: A double-edged sword even in the era of targeted therapies - part 1. <b>2018</b> , 17, 875-892	12
1180	Diagnosis and Management of Hepatitis in Patients on Checkpoint Blockade. <b>2018</b> , 23, 991-997	61
1179	Adverse Effects of Immune Checkpoint Therapy in Cancer Patients Visiting the Emergency Department of a Comprehensive Cancer Center. <b>2019</b> , 73, 79-87	46
1178	Immune tumor board: integral part in the multidisciplinary management of cancer patients treated with cancer immunotherapy. <b>2019</b> , 474, 485-495	2
1177	Response to: 'Checkpoint inhibitors and arthritis: seeking balance between victories and defeats' by Moura and Moura. <b>2019</b> , 78, e92	3
1176	To do or not to do: A concise update of current clinical controversies in immune checkpoint blockade. <b>2019</b> , 25, 663-673	7
1175	Severe arthritis and tenosynovitis caused by immune checkpoint blockade therapy with pembrolizumab (anti-PD-1 antibody). <b>2019</b> , 32, 419-421	2
1174	Review article: immune checkpoint inhibitors and the liver, from therapeutic efficacy to side effects. <b>2019</b> , 50, 872-884	18
1173	A Case of Immunotherapy-Induced Colitis Complicated by Perforation and Treated with Infliximab Postoperatively. <b>2019</b> , 2019, 9069354	4
1172	Late onset of nivolumab-induced severe gastroduodenitis and cholangitis in a patient with stage IV melanoma. <b>2019</b> , 11, 1005-1013	12
1171	Evolving Role of the Oncology Nurse in the Care of Patients with Melanoma. <b>2019</b> , 791-817	
1170	Melanoma Immunology and Immunotherapy. <b>2019</b> , 651-665	
1169	Immune checkpoint inhibitors-induced neuromuscular toxicity: From pathogenesis to treatment. <b>2019</b> , 24 Suppl 2, S74-S85	27
1168	The Role of the Lymphocyte Functional Crosstalk and Regulation in the Context of Checkpoint Inhibitor Treatment-Review. <b>2019</b> , 10, 2043	3
1167	Serious immune-related adverse events in patients with head and neck cancer after checkpoint blockade: Systematic review. <b>2019</b> , 41, 4036-4050	2
1166	Onkologische Immuntherapie und mögliche endokrine Nebenwirkungen bei Frauen. <b>2019</b> , 17, 185-188	
1165	A Review of Immune-Mediated Adverse Events in Melanoma. <b>2019</b> , 7, 101-120	14
1164	Bilateral Mydriasis and Serous Retinal Detachments Associated With Ipilimumab and 6-Melanoma Helper Peptide Vaccine for Cutaneous Melanoma. <b>2019</b> , 137, 1088-1090	2

1163	Immune checkpoint inhibitors in non-small cell lung cancer: A bird's eye view. <b>2019</b> , 233, 116713	25
1162	Checkpoint inhibitor-induced liver injury: A novel form of liver disease emerging in the era of cancer immunotherapy. <b>2019</b> , 36, 434-440	32
1161	The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of squamous cell carcinoma of the head and neck (HNSCC). <b>2019</b> , 7, 184	223
1160	Management of Adverse Events in Cancer Patients Treated With PD-1/PD-L1 Blockade: Focus on Asian Populations. <b>2019</b> , 10, 726	11
1159	To treat or not to treat: Patient exclusion in immune oncology clinical trials due to preexisting autoimmune disease. <b>2019</b> , 125, 3506-3513	15
1158	Immune landscape of hepatocellular carcinoma microenvironment: Implications for prognosis and therapeutic applications. <b>2019</b> , 39, 1608-1621	41
1157	Immune-Related Adverse Events: A Case-Based Approach. <b>2019</b> , 9, 530	22
1156	Hepatotoxicity of immune check point inhibitors: Approach and management. <b>2019</b> , 51, 1074-1078	19
1155	Delayed immune-related events (DIRE) after discontinuation of immunotherapy: diagnostic hazard of autoimmunity at a distance. <b>2019</b> , 7, 165	75
1154	The Impact and Toxicity of Checkpoint Inhibitors in Management of Lung Cancer. <b>2019</b> , 65-84	
1153	An Atypical Presentation of Lichen Planus-Like Reaction from Pembrolizumab. <b>2019</b> , 2019, 4065437	4
1152	Hypophysitis induced by immune checkpoint inhibitors in a Scottish melanoma population. <b>2019</b> , 6, MMT13	8
1151	Lichenoid dermatitis from immune checkpoint inhibitor therapy: An immune-related adverse event with mycosis-fungoides-like morphologic and molecular features. <b>2019</b> , 46, 872-877	3
1150	Letter: programmed cell death protein-1 (PD-1)-targeted immunotherapy in advanced hepatocellular carcinoma: efficacy and safety data from an international multicentre real-world cohort-more questions than answers. Authors' reply. <b>2019</b> , 50, 231-232	3
1149	Immune Checkpoint Inhibitor Toxicities. <b>2019</b> , 94, 1321-1329	60
1148	Pericardial effusion under nivolumab: case-reports and review of the literature. <b>2019</b> , 7, 266	19
1147	Exploiting autoimmunity unleashed by low-dose immune checkpoint blockade to treat advanced cancer. <b>2019</b> , 90, e12821	12
1146	The mechanisms of acute interstitial nephritis in the era of immune checkpoint inhibitors in melanoma. <b>2019</b> , 11, 1758835919875549	10

1145	Monoclonal Antibodies in Dermatocology-State of the Art and Future Perspectives. <b>2019</b> , 11,	6
1144	The Relative Risk of Immune-Related Liver Dysfunction of PD-1/PD-L1 Inhibitors Versus Chemotherapy in Solid Tumors: A Meta-Analysis of Randomized Controlled Trials. <b>2019</b> , 10, 1063	2
1143	Advances in Engineering Cells for Cancer Immunotherapy. <b>2019</b> , 9, 7889-7905	29
1142	Budesonide treatment for microscopic colitis from immune checkpoint inhibitors. <b>2019</b> , 7, 292	27
1141	Immune-Related Adverse Events Requiring Hospitalization: Spectrum of Toxicity, Treatment, and Outcomes. <b>2019</b> , 15, e825-e834	18
1140	Immune Checkpoint Inhibitor Toxicity in Head and Neck Cancer: From Identification to Management. <b>2019</b> , 10, 1254	10
1139	Adverse Events of Concurrent Immune Checkpoint Inhibitors and Antiangiogenic Agents: A Systematic Review. <b>2019</b> , 10, 1173	17
1138	[Supportive therapy and management of side effects in dermato-oncology]. <b>2019</b> , 70, 975-988	
1137	Pembrolizumab for anaplastic thyroid cancer: a case study. <b>2019</b> , 68, 1921-1934	10
1136	A "Crazy Paving" Pattern on CT Scan in a Patient Treated with Pembrolizumab. <b>2019</b> , 14, 242-245	2
1135	Nebenwirkungen bei Immuncheckpointinhibitoren (ICI). <b>2019</b> , 14, 338-352	
1134	Drug-induced liver injury. <b>2019</b> , 5, 58	148
1133	Concurrent therapy with immune checkpoint inhibitors and TNF $\alpha$ blockade in patients with gastrointestinal immune-related adverse events. <b>2019</b> , 7, 226	52
1132	C-reactive protein as an early marker of immune-related adverse events. <b>2019</b> , 145, 2625-2631	24
1131	Treatment-Free Survival: A Novel Outcome Measure of the Effects of Immune Checkpoint Inhibition-A Pooled Analysis of Patients With Advanced Melanoma. <b>2019</b> , 37, 3350-3358	23
1130	Anti-programmed cell death protein 1 (anti-PD1) immunotherapy induced autoimmune polyendocrine syndrome type II (APS-2): a case report and review of the literature. <b>2019</b> , 7, 241	11
1129	Immunotherapy for Lymphangiomyomatosis and Tuberous Sclerosis: Progress and Future Directions. <b>2019</b> , 156, 1062-1067	8
1128	Acute vascular events as a possibly related adverse event of immunotherapy: a single-institute retrospective study. <b>2019</b> , 120, 122-131	36



1127	Cardiotoxicity from immune checkpoint inhibitors. <b>2019</b> , 25, 100420	40
1126	Knowledge Gaps and Research Priorities in Immune Checkpoint Inhibitor-related Pneumonitis. An Official American Thoracic Society Research Statement. <b>2019</b> , 200, e31-e43	48
1125	Safety and Efficacy of Therapeutic Cancer Vaccines Alone or in Combination With Immune Checkpoint Inhibitors in Cancer Treatment. <b>2019</b> , 10, 1184	33
1124	Cardiovascular Toxicities of Immune Checkpoint Inhibitors: JACC Review Topic of the Week. <b>2019</b> , 74, 1714-1727	51
1123	Nivolumab-induced hypothyroidism followed by isolated ACTH deficiency. <b>2019</b> , 12,	10
1122	Varied phenotypes and management of immune checkpoint inhibitor-associated neuropathies. <b>2019</b> , 93, e1093-e1103	72
1121	Acute and Long-term Adverse Events Associated With Checkpoint Blockade. <b>2019</b> , 35, 150926	5
1120	Eltrombopag treatment for severe refractory thrombocytopenia caused by pembrolizumab. <b>2019</b> , 121, 4-6	7
1119	Addressing immune-related adverse events of cancer immunotherapy: how prepared are rheumatologists?. <b>2019</b> , 78, 860-862	13
1118	Targeted Cancer Therapies With Pericardial Effusions Requiring Pericardiocentesis Focusing on Immune Checkpoint Inhibitors. <b>2019</b> , 123, 1351-1357	27
1117	Immunotherapy Toxicity. <b>2019</b> , 33, 275-290	11
1116	Pharmacologic Considerations in the Disposition of Antibodies and Antibody-Drug Conjugates in Preclinical Models and in Patients. <b>2019</b> , 8,	13
1115	Immune checkpoint inhibitor-induced colitis as a predictor of survival in metastatic melanoma. <b>2019</b> , 68, 553-561	32
1114	ePROs in the follow-up of cancer patients treated with immune checkpoint inhibitors: a retrospective study. <b>2019</b> , 145, 765-774	17
1113	Assessment and management of cognitive changes in patients with cancer. <b>2019</b> , 125, 1958-1962	3
1112	Hepatotoxicity induced by immune checkpoint inhibitors: a comprehensive review including current and alternative management strategies. <b>2019</b> , 15, 231-244	45
1111	Hydroxychloroquine is a safe and effective steroid-sparing agent for immune checkpoint inhibitor-induced inflammatory arthritis. <b>2019</b> , 38, 1513-1519	27
1110	Immune Checkpoint Inhibitor Outcomes for Patients With Non-Small-Cell Lung Cancer Receiving Baseline Corticosteroids for Palliative Versus Nonpalliative Indications. <b>2019</b> , 37, 1927-1934	135

1109	Treatment Outcomes of Immune-Related Cutaneous Adverse Events. <b>2019</b> , 37, 2746-2758	84
1108	Management of Gastrointestinal Toxicity from Immune Checkpoint Inhibitor. <b>2019</b> , 26, 268-274	12
1107	A Review of Efficacy and Safety of Checkpoint Inhibitor for the Treatment of Acute Myeloid Leukemia. <b>2019</b> , 10, 609	31
1106	Evaluation of Readministration of Immune Checkpoint Inhibitors After Immune-Related Adverse Events in Patients With Cancer. <b>2019</b> , 5, 1310-1317	161
1105	Assessment of the Safety of Pembrolizumab in Patients With HIV and Advanced Cancer-A Phase 1 Study. <b>2019</b> , 5, 1332-1339	90
1104	Long Term Remission and Cardiac Toxicity of a Combination of Ipilimumab and Nivolumab in a Patient With Metastatic Head and Neck Carcinoma After Progression Following Nivolumab Monotherapy. <b>2019</b> , 9, 403	2
1103	Rapid Deep Responses With Nivolumab Plus Ipilimumab in Papillary Renal Cell Carcinoma With Sarcomatoid Dedifferentiation. <b>2019</b> , 17, 315-318	6
1102	Immunotherapy, cancer and rheumatic diseases. <b>2019</b> , 15, 249-251	
1101	Autoimmune Endocrine Dysfunctions Associated with Cancer Immunotherapies. <b>2019</b> , 20,	46
1100	Resumption of Immune Checkpoint Inhibitor Therapy After Immune-Mediated Colitis. <b>2019</b> , 37, 2738-2745	82
1099	The role of combination chemo-immunotherapy in advanced non-small cell lung cancer. <b>2019</b> , 19, 561-568	30
1098	Hematological Side Effects of Immune Checkpoint Inhibitors: The Example of Immune-Related Thrombocytopenia. <b>2019</b> , 10, 454	24
1097	Remembering the forgotten child: the role of immune checkpoint inhibition in patients with human immunodeficiency virus and cancer. <b>2019</b> , 7, 130	7
1096	Immunotherapy in Gynecologic Cancers: What We Know Now and Where We Are Headed. <b>2019</b> , 39, e126-e140	19
1095	Molecular and immune targets for Merkel cell carcinoma therapy and prevention. <b>2019</b> , 58, 1602-1611	2
1094	Challenge of immune-mediated adverse reactions in the emergency department. <b>2019</b> , 36, 369-377	6
1093	Case series of cancer patients who developed cholecystitis related to immune checkpoint inhibitor treatment. <b>2019</b> , 7, 118	15
1092	MiStImm: an agent-based simulation tool to study the self-nonsel self discrimination of the adaptive immune response. <b>2019</b> , 16, 9	1

1091	Immunotherapy in Older Adults: A Checkpoint to Palliation?. <b>2019</b> , 39, e110-e120	8
1090	Managing Immuno-Oncology Toxicity: Top 10 Innovative Institutional Solutions. <b>2019</b> , 39, 96-104	15
1089	Upper gastrointestinal symptoms and associated endoscopic and histological features in patients receiving immune checkpoint inhibitors. <b>2019</b> , 54, 538-545	22
1088	Identification and Management of Immune Checkpoint Inhibitor-Related Myocarditis: Use Troponin Wisely. <b>2019</b> , 37, 2201-2205	22
1087	Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance. <b>2019</b> , 16, 563-580	584
1086	Immune Checkpoint Inhibitor-Induced Myasthenia Gravis in a Patient with Advanced NSCLC and Remote History of Thymoma. <b>2019</b> , 20, e489-e491	4
1085	Vision loss with pembrolizumab treatment: A report of two cases. <b>2019</b> , 25, 1540-1546	9
1084	Adverse Events Following Cancer Immunotherapy: Obstacles and Opportunities. <b>2019</b> , 40, 511-523	94
1083	Expanding Therapeutic Options for Older Adults: Case-Based Updates in Breast and Lung Cancer. <b>2019</b> , 67, 1012-1019	2
1082	Trial Reporting in Immuno-Oncology (TRIO): An American Society of Clinical Oncology-Society for Immunotherapy of Cancer Statement. <b>2019</b> , 37, 72-80	12
1081	IL17A Blockade Successfully Treated Psoriasiform Dermatologic Toxicity from Immunotherapy. <b>2019</b> , 7, 860-865	40
1080	Combined immune therapy grade IV dermatitis in metastatic melanoma. <b>2019</b> , 15, 262-265	4
1079	Immunotherapy in Non-Small Cell Lung Cancer: Facts and Hopes. <b>2019</b> , 25, 4592-4602	241
1078	Stress Ulcer Prophylaxis in the Critically Ill Oncology Population. <b>2019</b> , 1-16	
1077	Immunotherapy-related hepatitis: real-world experience from a tertiary centre. <b>2019</b> , 10, 364-371	31
1076	Secondary sclerosing cholangitis with hemobilia induced by pembrolizumab: Case report and review of published work. <b>2019</b> , 49, 950-956	18
1075	Risk and incidence of fatal adverse events associated with immune checkpoint inhibitors: a systematic review and meta-analysis. <b>2019</b> , 15, 293-302	17
1074	Cardiac Toxicity Associated with Immune Checkpoint Inhibitors: Case Series and Review of the Literature. <b>2019</b> , 12, 260-276	41

1073	Expansion of pharmacist clinical services to optimize the management of immune checkpoint inhibitor toxicities. <b>2019</b> , 25, 954-960	6
1072	Management of Immune-Related Adverse Events Associated with Immune Checkpoint Inhibitor Therapy: a Minireview of Current Clinical Guidelines. <b>2019</b> , 6, 154-160	56
1071	Early introduction of selective immunosuppressive therapy associated with favorable clinical outcomes in patients with immune checkpoint inhibitor-induced colitis. <b>2019</b> , 7, 93	79
1070	Can an amino acid-based oral rehydration solution be effective in managing immune therapy-induced diarrhea?. <b>2019</b> , 127, 66-70	2
1069	Frequency and imaging features of abdominal immune-related adverse events in metastatic lung cancer patients treated with PD-1 inhibitor. <b>2019</b> , 44, 1917-1927	29
1068	Myocardial Dysfunction Associated with Cancer Therapy. <b>2019</b> , 71-79	
1067	Thyroid dysfunction induced by nivolumab: searching for disease patterns and outcomes. <b>2019</b> , 64, 605-613	30
1066	Avelumab (anti-PD-L1) as first-line switch-maintenance or second-line therapy in patients with advanced gastric or gastroesophageal junction cancer: phase 1b results from the JAVELIN Solid Tumor trial. <b>2019</b> , 7, 30	43
1065	Clinical outcomes of advanced stage cancer patients treated with sequential immunotherapy in phase 1 clinical trials. <b>2019</b> , 37, 1198-1206	8
1064	Myalgia and Arthralgia Immune-related Adverse Events (irAEs) in Patients With Genitourinary Malignancies Treated With Immune Checkpoint Inhibitors. <b>2019</b> , 17, 177-182	8
1063	Clinical characteristics and outcomes of immune checkpoint inhibitor-induced pancreatic injury. <b>2019</b> , 7, 31	47
1062	Antitumor response to microscopic melanoma in the gastric mucosa mimicking ipilimumab-induced gastritis. <b>2019</b> , 7, 41	6
1061	Acute liver injury in the context of immune checkpoint inhibitor-related colitis treated with infliximab. <b>2019</b> , 7, 47	16
1060	T cell co-stimulation and co-inhibition in cardiovascular disease: a double-edged sword. <b>2019</b> , 16, 325-343	39
1059	Nivolumab-Induced Concomitant Severe Upper and Lower Gastrointestinal Immune-Related Adverse Effects. <b>2019</b> , 6, e00249	6
1058	Complete Response and Immune-Mediated Adverse Effects With Checkpoint Blockade: Treatment of Mismatch Repair-Deficient Colorectal Neuroendocrine Carcinoma.. <b>2019</b> , 3, 1-7	0
1057	Toxicity of tumor immune checkpoint inhibitors-more attention should be paid. <b>2019</b> , 8, 1125-1133	5
1056	The effect of antibiotics on the clinical outcomes of patients with solid cancers undergoing immune checkpoint inhibitor treatment: a retrospective study. <b>2019</b> , 19, 1100	21

1055	Combination checkpoint inhibitor therapy induces multiple immune major related adverse events in the treatment of vaginal melanoma: A cautionary case report. <b>2019</b> , 30, 100508	1
1054	PD-1 Inhibitors: Safety of Use and Management of Immune-Mediated Adverse Reactions in Patients With Head and Neck Cancer. <b>2019</b> , 23, 627-638	0
1053	A systematic review on the emerging association between the occurrence of immune-related adverse events and clinical outcomes with checkpoint inhibitors in advanced cancer patients. <b>2019</b> , 46, 362-371	24
1052	Cardiac tamponade in a patient with stage IV lung adenocarcinoma treated with pembrolizumab. <b>2019</b> , 11, 1533-1540	5
1051	Immunotherapy in Bladder Cancer. <b>2019</b> ,	14
1050	A Case of Severe Seronegative Inflammatory Arthritis due to Nivolumab and Review of the Literature. <b>2019</b> , 2019, 1326734	0
1049	Immune-Mediated Colitis. <b>2019</b> , 17, 506-523	2
1048	Incidence rates of immune-related adverse events and their correlation with response in advanced solid tumours treated with NIVO or NIVO+IPI: a systematic review and meta-analysis. <b>2019</b> , 7, 341	74
1047	Immune Checkpoint Inhibitor Associated Rheumatic Adverse Events: a Review of Their Presentations and Treatments. <b>2019</b> , 5, 272-289	1
1046	Superimposed Clostridium difficile Infection During Checkpoint Inhibitor Immunotherapy-induced Colitis. <b>2019</b> , 42, 350-353	10
1045	Checkpoint Inhibitor-Associated Autoimmunity: What a Rheumatologist Needs to Know. <b>2019</b> ,	
1044	Immunotherapy in metastatic melanoma: a novel scenario of new toxicities and their management. <b>2019</b> , 6, MMT30	8
1043	Severe Immune-Related Pneumonitis With PD-1 Inhibitor After Progression on Previous PD-L1 Inhibitor in Small Cell Lung Cancer: A Case Report and Review of the Literature. <b>2019</b> , 9, 1437	11
1042	Immune Checkpoint Inhibitor-Associated Cardiotoxicity: Current Understanding on Its Mechanism, Diagnosis and Management. <b>2019</b> , 10, 1350	42
1041	Musculoskeletal Effects of Antineoplastic Agents. <b>2019</b> , 27, 834-839	1
1040	Management of pulmonary toxicity associated with immune checkpoint inhibitors. <b>2019</b> , 28,	34
1039	Cardiac toxicities of anticancer treatments: chemotherapy, targeted therapy and immunotherapy. <b>2019</b> , 34, 441-450	13
1038	Neurotoxicity associated with cancer immunotherapy: immune checkpoint inhibitors and chimeric antigen receptor T-cell therapy. <b>2019</b> , 32, 500-510	37

1037	Pulmonary complications of immune checkpoint inhibitors in patients with nonsmall cell lung cancer. <b>2019</b> , 28,	48
1036	Proceedings From the Global Cardio-Oncology Summit: The Top 10 Priorities to Actualize for CardioOncology. <b>2019</b> , 1, 256-272	14
1035	Toxicities associated with checkpoint inhibitors-an overview. <b>2019</b> , 58, vii7-vii16	62
1034	Emerging Translational Opportunities in Comparative Oncology With Companion Canine Cancers: Radiation Oncology. <b>2019</b> , 9, 1291	11
1033	An unusual skin reaction in uveal melanoma during treatment with nivolumab: extragenital lichen sclerosus. <b>2019</b> , 30, 969-972	4
1032	[Toxicities of immune checkpoint inhibitors and their management]. <b>2019</b> , 35, 949-956	1
1031	Dysprosium metallicum, a new homeopathic medicine in oncological supportive care for the prevention of side effects of immunotherapy. <b>2019</b> , 10, e9-e13	1
1030	Diagnosis and Management of Immune Checkpoint Inhibitor-Associated Neurologic Toxicity: Illustrative Case and Review of the Literature. <b>2019</b> , 24, 435-443	44
1029	Diagnosis and Management of Immune Checkpoint Inhibitor-Associated Renal Toxicity: Illustrative Case and Review. <b>2019</b> , 24, 735-742	31
1028	Can Immune Checkpoint Inhibitors Induce Microscopic Colitis or a Brand New Entity?. <b>2019</b> , 25, 385-393	33
1027	Impact of Checkpoint Inhibitor Pneumonitis on Survival in NSCLC Patients Receiving Immune Checkpoint Immunotherapy. <b>2019</b> , 14, 494-502	64
1026	Pembrolizumab-induced pneumonitis with a perilymphatic nodular pattern in a lung cancer patient: A radio-pathologic correlation. <b>2019</b> , 26, 168-170	4
1025	Endocrine and metabolic adverse effects of immune checkpoint inhibitors: an overview (what endocrinologists should know). <b>2019</b> , 42, 745-756	36
1024	Emerging Role of Combination Immunotherapy in the First-line Treatment of Advanced Renal Cell Carcinoma: A Review. <b>2019</b> , 5, 411-421	36
1023	Safety and Tolerability of Immune Checkpoint Inhibitors (PD-1 and PD-L1) in Cancer. <b>2019</b> , 42, 281-294	45
1022	New therapeutic perspectives to manage refractory immune checkpoint-related toxicities. <b>2019</b> , 20, e54-e64	93
1021	Management of immune-related adverse events resulting from immune checkpoint blockade. <b>2019</b> , 19, 209-222	12
1020	Guillain-Barré Syndrome Related to Nivolumab: Case Report of a Patient With Urothelial Cancer and Review of the Literature. <b>2019</b> , 17, e360-e364	6

1019	Nephrotoxicity of immune checkpoint inhibitors beyond tubulointerstitial nephritis: single-center experience. <b>2019</b> , 7, 2	135
1018	Comparing the effects of different cell death programs in tumor progression and immunotherapy. <b>2019</b> , 26, 115-129	46
1017	Cases from the irAE Tumor Board: A Multidisciplinary Approach to a Patient Treated with Immune Checkpoint Blockade Who Presented with a New Rash. <b>2019</b> , 24, 4-8	5
1016	Characterisation of rare haematological immune-related toxicities. <b>2019</b> , 6, e10-e11	
1015	Rheumatic diseases associated with immune checkpoint inhibitors in cancer immunotherapy. <b>2019</b> , 29, 721-732	8
1014	Immunotherapy, Cancer and Rheumatological Diseases: A Review of the Literature and a Series of Cases in a University Hospital. <b>2020</b> , 16, 413-415	
1013	An immunotherapy survivor population: health-related quality of life and toxicity in patients with metastatic melanoma treated with immune checkpoint inhibitors. <b>2020</b> , 28, 561-570	19
1012	Ocular Adverse Events following Use of Immune Checkpoint Inhibitors for Metastatic Malignancies. <b>2020</b> , 28, 854-859	21
1011	Targeting the tumor microenvironment to overcome immune checkpoint blockade therapy resistance. <b>2020</b> , 220, 88-96	14
1010	Adverse Events of Novel Therapies for Hematologic Malignancies: What Emergency Physicians Should Know. <b>2020</b> , 75, 264-286	3
1009	Immune-related dermatologic toxicities: to make a long story short. <b>2020</b> , 39, 10-12	1
1008	Stress Ulcer Prophylaxis in the Critically Ill Oncology Population. <b>2020</b> , 137-151	
1007	Perspectives on Treatment of Metastatic Colorectal Cancer with Immune Checkpoint Inhibitor Therapy. <b>2020</b> , 25, 33-45	54
1006	Immune-related Adverse Events Associated with Cancer Immunotherapy: A Review for the Practicing Rheumatologist. <b>2020</b> , 47, 166-175	22
1005	Immune-related adverse events in the gastrointestinal tract: diagnostic utility of upper gastrointestinal biopsies. <b>2020</b> , 76, 233-243	35
1004	Cardiovascular toxicity of immune checkpoint inhibitors in cancer patients: A review when cardiology meets immuno-oncology. <b>2020</b> , 119, 1461-1475	28
1003	Local therapy for cancer therapy-associated uveitis: a case series and review of the literature. <b>2020</b> , 104, 703-711	12
1002	Successful Retreatment Using Pembrolizumab for Non-small-cell Lung Cancer After Severe Immune-related Hepatitis: A Case Report. <b>2020</b> , 21, e30-e32	3

1001	The Role of Pharmacists in Managing Adverse Events Related to Immune Checkpoint Inhibitor Therapy. <b>2020</b> , 33, 338-349	5
1000	Biomarkers for immune checkpoint inhibition in non-small cell lung cancer (NSCLC). <b>2020</b> , 126, 260-270	89
999	Diagnosis and Management of Rare Immune-Related Adverse Events. <b>2020</b> , 25, 6-14	18
998	Beyond neurotransmission: acetylcholine in immunity and inflammation. <b>2020</b> , 287, 120-133	27
997	Fatal hepatic necrosis after nivolumab as a bridge to liver transplant for HCC: Are checkpoint inhibitors safe for the pretransplant patient?. <b>2020</b> , 20, 879-883	32
996	Immunotoxicity from checkpoint inhibitor therapy: clinical features and underlying mechanisms. <b>2020</b> , 159, 167-177	35
995	The renal adverse effects of cancer immunotherapy. <b>2020</b> , 33, 467-481	5
994	Imaging and clinical manifestations of immune checkpoint inhibitor-related colitis in cancer patients treated with monotherapy or combination therapy. <b>2020</b> , 45, 3028-3035	3
993	The "ART" of Epigenetics in Melanoma: From histone "Alterations, to Resistance and Therapies". <b>2020</b> , 10, 1777-1797	31
992	Emerging PD-1 and PD-1L inhibitors-associated myopathy with a characteristic histopathological pattern. <b>2020</b> , 19, 102455	29
991	Immune Checkpoint Inhibitors-Related Cardiotoxicity. <b>2020</b> , 27, e591-e598	7
990	Clinical Characteristics and Adverse Impact of Hepatotoxicity due to Immune Checkpoint Inhibitors. <b>2020</b> , 115, 251-261	20
989	New insight in endocrine-related adverse events associated to immune checkpoint blockade. <b>2020</b> , 34, 101370	26
988	Immune-Related Adverse Events in the Setting of PD-1/L1 Inhibitor Combination Therapy. <b>2020</b> , 25, e398-e404	9
987	Drug-Induced Liver Injury in the Setting of Chronic Liver Disease. <b>2020</b> , 24, 89-106	6
986	Patient-Reported Outcomes From Patients Receiving Immunotherapy or Chemoimmunotherapy for Metastatic Non-Small-Cell Lung Cancer in Clinical Practice. <b>2020</b> , 21, 255-263.e4	10
985	Immune-Related Pancytopenia Induced by Anti-PD-1 Therapy - Interrupt or Continue Treatment - The Role of Immunohistochemical Examination. <b>2019</b> , 12, 820-828	1
984	Atezolizumab for children and young adults with previously treated solid tumours, non-Hodgkin lymphoma, and Hodgkin lymphoma (iMATRIX): a multicentre phase 1-2 study. <b>2020</b> , 21, 134-144	47



983	Combination Therapy of Ipilimumab and Nivolumab-associated Toxic Epidermal Necrolysis (TEN) in a Patient With Metastatic Melanoma: A Case Report and Literature Review. <b>2020</b> , 43, 89-92	16
982	Neurological immune-related adverse events associated with immune checkpoint inhibitors: A review of the literature. <b>2020</b> , 16, 291-298	6
981	Practical Considerations and Challenges for Germline Genetic Testing in Patients With Prostate Cancer: Recommendations From the Germline Genetics Working Group of the PCCTC. <b>2020</b> , 16, 811-819	16
980	Immune Checkpoint Inhibitors and Cardiac Toxicity in Patients Treated for Non-Small Lung Cancer: A Review. <b>2020</b> , 21,	21
979	Management of the Adverse Effects of Immune Checkpoint Inhibitors. <b>2020</b> , 8,	11
978	Severe combined cardiac and neuromuscular toxicity from immune checkpoint blockade: an institutional case series. <b>2020</b> , 6, 21	8
977	Management of Side Effects of Systemic Therapies for Hepatocellular Carcinoma: Guide for the Hepatologist. <b>2020</b> , 24, 755-769	4
976	Reversible primary adrenal insufficiency related to anti-programmed cell-death 1 protein active immunotherapy: Insight into an unforeseen outcome of a rare immune-related adverse event. <b>2020</b> , 89, 107050	3
975	Classical Examples of the Concept of the ASIA Syndrome. <b>2020</b> , 10,	19
974	Uncoupling Therapeutic Efficacy from Immune-Related Adverse Events in Immune Checkpoint Blockade. <b>2020</b> , 23, 101580	10
973	The Critical Role of the Oncology Nurse as a Partner in the Management of Patients With Advanced Kidney Cancer: Toxicity Management, Symptom Control, and Palliative Care. <b>2020</b> , 26, 460-463	1
972	The Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of acute leukemia. <b>2020</b> , 8,	2
971	Immune-Mediated Colitis due to Concurrent Ipilimumab and Nivolumab Therapy Treated With Infliximab. <b>2020</b> , 27, e415-e417	0
970	Liver toxicity as a limiting factor to the increasing use of immune checkpoint inhibitors. <b>2020</b> , 2, 100170	23
969	Pneumonitis Induced by Immune Checkpoint Inhibitors: From Clinical Data to Translational Investigation. <b>2020</b> , 10, 1785	14
968	Activation of CD8 T cells accelerates anti-PD-1 antibody-induced psoriasis-like dermatitis through IL-6. <b>2020</b> , 3, 571	9
967	Management of metabolic adverse events of targeted therapies and immune checkpoint inhibitors in cancer patients: an Associazione Italiana Oncologia Medica (AIOM)/Associazione Medici Diabetologi (AMD)/Societ` Italiana Farmacologia (SIF) multidisciplinary consensus position paper. <b>2020</b> , 154, 103066	2
966	Immune escape: A critical hallmark in solid tumors. <b>2020</b> , 258, 118110	48

965	Durvalumab Immunotherapy: Nursing Management of Immune-Related Adverse Events During the Journey of Patients With Stage III Non-Small Cell Lung Cancer. <b>2020</b> , 24, 277-283	1
964	Immune Checkpoint Inhibitor-Induced Myasthenia Gravis. <b>2020</b> , 11, 634	18
963	and expression by clinical, HLA, immune, and microbial correlates across 34 human cancers and matched normal tissues: implications for SARS-CoV-2 COVID-19. <b>2020</b> , 8,	26
962	Management of Immune Checkpoint Inhibitor-Related Rheumatological Toxicities. <b>2020</b> , 20, 25-34	
961	Development of autoimmune diabetes with severe diabetic ketoacidosis and immune-related thyroiditis secondary to durvalumab: a case report. <b>2020</b> , 9, 2149-2156	2
960	Multidisciplinary Clinical Approach to Cancer Patients with Immune-Related Adverse Events Induced by Checkpoint Inhibitors. <b>2020</b> , 12,	6
959	Bilateral Posterior Uveitis and Retinal Detachment During Immunotherapy: A Case Report and Literature Review. <b>2020</b> , 10, 549168	2
958	The quality of reporting general safety parameters and immune-related adverse events in clinical trials of FDA-approved immune checkpoint inhibitors. <b>2020</b> , 20, 1128	4
957	Optimizing current standard of care therapy for stage III non-small cell lung cancer. <b>2020</b> , 9, 2033-2039	1
956	Sarcoidosis and Cancer: A Complex Relationship. <b>2020</b> , 7, 594118	12
955	Evidence for interleukin 17 involvement in severe immune-related neuroendocrine toxicity. <b>2020</b> , 141, 218-224	6
954	Head and neck squamous cell carcinoma. <b>2020</b> , 6, 92	397
953	Estimation of US patients with cancer who may respond to cytotoxic chemotherapy. <b>2020</b> , 6, FSO600	3
952	Water extract of sporoderm-broken spores of Ganoderma lucidum enhanced pd-l1 antibody efficiency through downregulation and relieved complications of pd-l1 monoclonal antibody. <b>2020</b> , 131, 110541	2
951	Immune Checkpoint Inhibitor-Related Pneumonitis. <b>2020</b> , 99, 932-942	9
950	Immune Thrombocytopenia Induced by Immune Checkpoint Inhibitors in Solid Cancer: Case Report and Literature Review. <b>2020</b> , 10, 530478	4
949	Neuro-ophthalmic Complications of Immune Checkpoint Inhibitors: A Systematic Review. <b>2020</b> , 12, 139-167	5
948	How to manage patients with corticosteroids in oncology in the era of immunotherapy?. <b>2020</b> , 141, 239-251	10

947	Impact of age on the toxicity of immune checkpoint inhibition. <b>2020</b> , 8,	11
946	Revisiting the association between skin toxicity and better response in advanced cancer patients treated with immune checkpoint inhibitors. <b>2020</b> , 18, 430	3
945	Immune-Related Neuromuscular Complications of Checkpoint Inhibitors. <b>2020</b> , 22, 1	0
944	Immune checkpoint inhibitor-induced inflammatory arthritis: identification and management. <b>2020</b> , 16, 771-785	3
943	Best practices for detection, assessment and management of suspected immune-mediated liver injury caused by immune checkpoint inhibitors during drug development. <b>2020</b> , 114, 102514	14
942	Clinical burden of immune checkpoint inhibitor-induced pneumonitis. <b>2020</b> , 58, 305-319	6
941	Combined C-Reactive Protein and Novel Inflammatory Parameters as a Predictor in Cancer-What Can We Learn from the Hematological Experience?. <b>2020</b> , 12,	14
940	[Third degree atrio-ventricular blockade during a myocarditis occurring under anti-PD1 : Case report and literature review]. <b>2020</b> , 41, 284-288	2
939	Allotterism of Nicotinic Acetylcholine Receptors: Therapeutic Potential for Neuroinflammation Underlying Brain Trauma and Degenerative Disorders. <b>2020</b> , 21,	9
938	An overview of the immune mechanisms of viral myocarditis. <b>2020</b> , 30, 1-14	21
937	Understanding Response to Immunotherapy Using Standard of Care and Experimental Imaging Approaches. <b>2020</b> , 108, 242-257	2
936	Neurologic Manifestations of Systemic Disease: Peripheral Nervous System. <b>2020</b> , 22, 1	
935	Pulmonary toxicity of systemic lung cancer therapy. <b>2020</b> , 25 Suppl 2, 72-79	8
934	Mechanisms of Immune-Related Complications in Cancer Patients Treated with Immune Checkpoint Inhibitors. <b>2021</b> , 106, 123-136	6
933	SBRT combined with PD-1/PD-L1 inhibitors in NSCLC treatment: a focus on the mechanisms, advances, and future challenges. <b>2020</b> , 13, 105	17
932	Lessons to be Learnt from Real-World Studies on Immune-Related Adverse Events with Checkpoint Inhibitors: A Clinical Perspective from Pharmacovigilance. <b>2020</b> , 15, 449-466	37
931	Brief report: inhaled corticosteroid use and the risk of checkpoint inhibitor pneumonitis in patients with advanced cancer. <b>2020</b> , 69, 2403-2408	3
930	Immune checkpoint inhibitor toxicities: systems-based approaches to improve patient care and research. <b>2020</b> , 21, e398-e404	35

929	Reintroduction of immune-checkpoint inhibitors after immune-related meningitis: a case series of melanoma patients. <b>2020</b> , 8,	11
928	Untangling the Multidisciplinary Care Web: Streamlining Care Through an Immune-Related Adverse Events (IRAE) Tumor Board. <b>2020</b> , 15, 541-548	5
927	Rheumatic immune-related adverse events induced by immune checkpoint inhibitors. <b>2021</b> , 17, 178-185	12
926	Hypoproteinemia being a manifestation of immunotherapy-related liver dysfunction. <b>2020</b> , 8, 889	0
925	Management of Immune-Related Cutaneous Adverse Reactions to PD-1 and PD-L1 Inhibitors for the Inpatient Dermatologist. <b>2020</b> , 9, 231-243	2
924	First-Line Immune-Checkpoint Inhibitors in Non-Small Cell Lung Cancer: Current Landscape and Future Progress. <b>2020</b> , 11, 578091	22
923	Feasibility of Integrating a Mobile Decision-Support App into a Multicomponent CME Initiative: Developing Clinician Competence at the Point of Care. <b>2020</b> , 9, 1834762	
922	Case of anti-Zic4 antibody-mediated cerebellar toxicity induced by dual checkpoint inhibition in head and neck squamous cell carcinoma. <b>2020</b> , 13,	4
921	Multidisciplinary Approach to Immune-Mediated Diarrhea and Colitis From Immunotherapy for Cancer. <b>2020</b> , 16, 462-463	0
920	Commentary: The Effects of Postoperative Neurological Deficits on Survival in Patients With Single Brain Metastasis. <b>2020</b> , 19, E552-E554	
919	Multisystem Immune-Related Adverse Events Associated With Immune Checkpoint Inhibitors for Treatment of Non-Small Cell Lung Cancer. <b>2020</b> , 6, 1952-1956	79
918	Predictive Biomarkers of Immune Checkpoint Inhibitors-Related Toxicities. <b>2020</b> , 11, 2023	12
917	ESMO consensus conference recommendations on the management of locoregional melanoma: under the auspices of the ESMO Guidelines Committee. <b>2020</b> , 31, 1449-1461	19
916	Imaging findings of immune checkpoint inhibitor associated pancreatitis. <b>2020</b> , 131, 109250	7
915	How I treat cancer: treatment of rheumatological side effects of immunotherapy. <b>2019</b> , 4, e000529	5
914	Multinational Association of Supportive Care in Cancer (MASCC) 2020 clinical practice recommendations for the management of severe dermatological toxicities from checkpoint inhibitors. <b>2020</b> , 28, 6119-6128	6
913	Multinational Association of Supportive Care in Cancer (MASCC) 2020 clinical practice recommendations for the management of immune-mediated cardiovascular, rheumatic, and renal toxicities from checkpoint inhibitors. <b>2020</b> , 28, 6159-6173	3
912	Outcomes following immunotherapy re-challenge after immune-related adverse event: systematic review and meta-analysis. <b>2020</b> , 12, 1183-1193	6

911	Eight pillars of oncorheumatology: Crossroads between malignancies and musculoskeletal diseases. <b>2020</b> , 19, 102658	4
910	Schilddrüsenfunktionsstörungen unter Immuncheckpoint-Inhibitor-Therapie. <b>2020</b> , 13, 115-118	
909	Microbiota and Cancer: The Emerging Beneficial Role of Bifidobacteria in Cancer Immunotherapy. <b>2020</b> , 11, 575072	14
908	MASCC 2020 recommendations for the management of immune-related adverse events of patients undergoing treatment with immune checkpoint inhibitors. <b>2020</b> , 28, 6107-6110	9
907	Immune Related Adverse Events: Classification and Management Approaches in Advanced Kidney Cancer. <b>2020</b> , 26, 432-440	1
906	Diagnosis and Treatment of Rheumatic Adverse Events Related to Immune Checkpoint Inhibitors. <b>2020</b> , 2020, 2640273	4
905	Multinational Association of Supportive Care in Cancer (MASCC) 2020 clinical practice recommendations for the management of severe gastrointestinal and hepatic toxicities from checkpoint inhibitors. <b>2020</b> , 28, 6129-6143	7
904	Achieving efficacious immunotherapy for patients with glioblastoma. <b>2020</b> , 20, 909-911	
903	PD-1 Inhibitor Therapy in a Patient with Preexisting P-ANCA Vasculitis: A Case Report and Review of the Literature. <b>2020</b> , 2020, 3428945	1
902	Radiation recall pneumonitis induced by PD-1/PD-L1 blockades: mechanisms and therapeutic implications. <b>2020</b> , 18, 275	13
901	Adverse Effects of Anti-PD-1/PD-L1 Therapy in Non-small Cell Lung Cancer. <b>2020</b> , 10, 554313	13
900	Multinational Association of Supportive Care in Cancer (MASCC) 2020 clinical practice recommendations for the management of immune-related adverse events: pulmonary toxicity. <b>2020</b> , 28, 6145-6157	6
899	Evaluation of Checkpoint Inhibitors in Cancer Patients With End-stage Renal Disease on Hemodialysis: Case Series and Review of the Literature. <b>2020</b> , 43, 244-249	5
898	Immunotherapy-Related Colitis: An Emerging Challenge and a Quest for Prospective Data. <b>2020</b> , 16, 464-465	0
897	Management of Cardiac Toxicity Induced by Chemotherapy. <b>2020</b> , 9,	8
896	Diagnosis and management of immune-related adverse effects of immune checkpoint therapy in the emergency department. <b>2020</b> , 1, 1637-1659	8
895	Anti-PD-1 and Anti-PD-L1 Monoclonal Antibodies in People Living with HIV and Cancer. <b>2020</b> , 17, 547-556	6
894	Endocrine Adverse Events of Nivolumab in Non-Small Cell Lung Cancer Patients-Literature Review. <b>2020</b> , 12,	8

893	Immunotherapy, cancer and rheumatological diseases: A review of the literature and a series of cases in a university hospital. <b>2020</b> , 16, 413-415	
892	Immune-Related Neurological Toxicities of PD-1/PD-L1 Inhibitors in Cancer Patients: A Systematic Review and Meta-Analysis. <b>2020</b> , 11, 595655	3
891	Immune checkpoint inhibitor-associated myopathy: a clinicoseropathologically distinct myopathy. <b>2020</b> , 2, fcaa181	16
890	Strategies for improving the management of immune-related adverse events. <b>2020</b> , 8,	29
889	A case of large-cell lung carcinoma successfully treated with pembrolizumab but complicated with cholangitis. <b>2020</b> , 31, 101197	3
888	Aging and immunotherapies: New horizons for the golden ages. <b>2020</b> , 1, 30-44	3
887	Therapeutic strategies to remodel immunologically cold tumors.. <b>2020</b> , 9, e1226	1
886	Toxicities from immunotherapy: From clinical trials to real-world clinical practice. <b>2020</b> , 155, 541-547	
885	Beyond Blocking: Engineering RNAi-Mediated Targeted Immune Checkpoint Nanoblocker Enables T-Cell-Independent Cancer Treatment. <b>2020</b> ,	10
884	Diagnostic utility of CT for suspected immune checkpoint inhibitor enterocolitis. <b>2020</b> , 8,	2
883	Clinicopathological characteristics and management of colitis with anti-PD1 immunotherapy alone or in combination with ipilimumab. <b>2020</b> , 8,	6
882	Review of Adjuvant Therapies in Renal Cell Carcinoma: Evidence to Date. <b>2020</b> , 13, 12301-12316	6
881	Nebenwirkungen immunonkologischer Therapien. <b>2020</b> , 45, 535-543	
880	[Bullous pemphigoid under anti-PD1 therapy]. <b>2020</b> , 147, 795-797	
879	When steroids are not enough in immune-related hepatitis: current clinical challenges discussed on the basis of a case report. <b>2020</b> , 8,	10
878	Cardiovascular toxicity in patients treated with immunotherapy for metastatic non-small cell lung cancer: A SEER-medicare study: CVD outcomes with the use of ICI in mNSCLC. <b>2020</b> , 150, 172-177	3
877	Myositis and myasthenia during nivolumab administration for advanced lung cancer: a case report and review of the literature. <b>2020</b> , 31, 540-544	6
876	Current evidence and future perspectives of immune-checkpoint inhibitors in unresectable malignant pleural mesothelioma. <b>2020</b> , 8,	12

875	Immune checkpoint inhibitor-related colitis assessment and prognosis: can IBD scoring point the way?. <b>2020</b> , 123, 207-215	16
874	Association of immune-related pneumonitis with the efficacy of PD-1/PD-L1 inhibitors in non-small cell lung cancer. <b>2020</b> , 12, 1758835920922033	12
873	What's the Price? Toxicities of Targeted Therapies in Breast Cancer Care. <b>2020</b> , 40, 55-70	6
872	Oncologic Emergencies: Immune-Based Cancer Therapies and Complications. <b>2020</b> , 21, 566-580	7
871	Immune-related adverse events of checkpoint inhibitors. <b>2020</b> , 6, 38	234
870	Compromise or not? A case report of successful treatment of pembrolizumab-induced hepatitis in a patient with non-small cell lung cancer with low-dose methylprednisolone and bicyclol. <b>2020</b> , 11, 2023-2030	3
869	[Side effects of novel cancer immunotherapies]. <b>2020</b> , 15, 1-13	3
868	Reactive cutaneous capillary endothelial proliferation in advanced hepatocellular carcinoma patients treated with camrelizumab: data derived from a multicenter phase 2 trial. <b>2020</b> , 13, 47	29
867	Nivolumab-induced IgA nephropathy in a patient with advanced gastric cancer: A case report. <b>2020</b> , 99, e20464	7
866	Checkpoint Inhibitor Pneumonitis: Mechanisms, Characteristics, Management Strategies, and Beyond. <b>2020</b> , 22, 56	9
865	A systematic review and meta-analysis of immune-mediated liver dysfunction in non-small cell lung cancer. <b>2020</b> , 83, 106537	6
864	Immune checkpoint inhibitor-related dermatologic adverse events. <b>2020</b> , 83, 1255-1268	76
863	Treatment of immune checkpoint inhibitor-induced inflammatory arthritis. <b>2020</b> , 32, 315-320	9
862	Diagnosis, monitoring, and management of adverse events from immune checkpoint inhibitor therapy. <b>2020</b> , 27, S43-S50	4
861	A case of dual-mechanism immune-related anaemia in a patient with metastatic melanoma treated with nivolumab and ipilimumab. <b>2020</b> , 8,	5
860	A review of cancer immunotherapy: from the past, to the present, to the future. <b>2020</b> , 27, S87-S97	182
859	Cancer immunotherapy: dawn of the death of cancer?. <b>2020</b> , 1-18	1
858	Magnetic Resonance Imaging to Detect Cardiovascular Effects of Cancer Therapy: State-of-the-Art Review. <b>2020</b> , 2, 270-292	10

857	Regulatory and strategic considerations for addressing immunogenicity and related responses in biopharmaceutical development programs. <b>2020</b> , 4, 547-555	2
856	Uveitis Induced by Biological Agents Used in Cancer Therapy. <b>2020</b> , 1-5	6
855	Rheumatic immune-related adverse events associated with cancer immunotherapy: A nationwide multi-center cohort. <b>2020</b> , 19, 102595	22
854	Cases from the Immune-Related Adverse Event Tumor Board: Diagnosis and Management of Immune Checkpoint Blockade-Induced Diabetes. <b>2020</b> , 25, 921-924	4
853	Advances in immune neoadjuvant/adjuvant therapy-related adverse events of non-small cell lung cancer. <b>2020</b> ,	2
852	Intranasal Therapeutic Peptide Vaccine Promotes Efficient Induction and Trafficking of Cytotoxic T Cell Response for the Clearance of HPV Vaginal Tumors. <b>2020</b> , 8,	5
851	Pulmonary Complications of Immunotherapy. <b>2020</b> , 41, 295-305	1
850	Evolving insights into the mechanisms of toxicity associated with immune checkpoint inhibitor therapy. <b>2020</b> , 86, 1778-1789	18
849	Major Adverse Cardiovascular Events and the Timing and Dose of Corticosteroids in Immune Checkpoint Inhibitor-Associated Myocarditis. <b>2020</b> , 141, 2031-2034	60
848	Immune-related (IR)-pneumonitis during the COVID-19 pandemic: multidisciplinary recommendations for diagnosis and management. <b>2020</b> , 8,	12
847	Infectious Complications of Immune Checkpoint Inhibitors. <b>2020</b> , 34, 235-243	1
846	Mucosal inflammation predicts response to systemic steroids in immune checkpoint inhibitor colitis. <b>2020</b> , 8,	15
845	Immune Checkpoint Inhibitors and Immune-Related Adverse Drug Reactions: Data From Italian Pharmacovigilance Database. <b>2020</b> , 11, 830	7
844	Chronic immune checkpoint inhibitor pneumonitis. <b>2020</b> , 8,	17
843	Gastrointestinal and Hepatic Complications of Immunotherapy: Current Management and Future Perspectives. <b>2020</b> , 22, 15	12
842	Case 9-2020: A 64-Year-Old Man with Shortness of Breath, Cough, and Hypoxemia. <b>2020</b> , 382, 1150-1159	3
841	Non-IBD and Noninfectious Colitis. <b>2020</b> , 1-21	
840	Tumor cell-intrinsic PD-1 receptor is a tumor suppressor and mediates resistance to PD-1 blockade therapy. <b>2020</b> , 117, 6640-6650	51



839	Management of dermatologic adverse events from cancer therapies: recommendations of an expert panel. <b>2020</b> , 95, 221-237	15
838	Chronic inflammatory arthritis following checkpoint inhibitor therapy for cancer: game changing implications. <b>2020</b> , 79, 309-311	7
837	Immune checkpoint inhibitor associated neurotoxicity: Much more than meets the eye. <b>2020</b> , 221, 72-74	
836	Nivolumab-induced immune-mediated neurotoxicity in Hodgkin lymphoma. <b>2020</b> , 33, 59-61	
835	How Can Immune Checkpoint Inhibitors Cause Hyperprogression in Solid Tumors?. <b>2020</b> , 11, 492	21
834	Risk of Gastrointestinal Adverse Events in Cancer Patients Treated With Immune Checkpoint Inhibitor Plus Chemotherapy: A Systematic Review and Meta-Analysis. <b>2020</b> , 10, 197	4
833	The role of immunosuppressive agents in the management of severe and refractory immune-related adverse events. <b>2020</b> , 16, 201-210	10
832	Adverse cardiac effects of cancer therapies: cardiotoxicity and arrhythmia. <b>2020</b> , 17, 474-502	126
831	Moving towards personalized treatments of immune-related adverse events. <b>2020</b> , 17, 504-515	90
830	Clinical Characteristics and Treatment of Immune-Related Adverse Events of Immune Checkpoint Inhibitors. <b>2020</b> , 20, e9	61
829	Hepatotoxicity From Immune Checkpoint Inhibitors: A Systematic Review and Management Recommendation. <b>2020</b> , 72, 315-329	60
828	The 2016-2019 ImmunoTOX assessment board report of collaborative management of immune-related adverse events, an observational clinical study. <b>2020</b> , 130, 39-50	17
827	Cardiovascular immune-related adverse events: Evaluation, diagnosis and management. <b>2020</b> , 16, 232-240	9
826	Immune Checkpoint Inhibitor-Mediated Diarrhea and Colitis: A Clinical Review. <b>2020</b> , 16, 453-461	12
825	FDG PET/CT for Assessment of Immune Therapy: Opportunities and Understanding Pitfalls. <b>2020</b> , 50, 518-531	9
824	Keeping Patients With Cancer Exercising in the Age of COVID-19. <b>2020</b> , 16, 656-664	26
823	Real-World Outcomes of Nivolumab in Patients With Unresectable Hepatocellular Carcinoma in an Endemic Area of Hepatitis B Virus Infection. <b>2020</b> , 10, 1043	13
822	The safety of first and subsequent lines of PD-1/PD-L1 inhibitors monotherapy in non-small cell lung cancer patients: a meta-analysis. <b>2020</b> , 9, 3231-3241	4

821	Interstitial lung abnormalities detected incidentally on CT: a Position Paper from the Fleischner Society. <b>2020</b> , 8, 726-737	77
820	Quantitative Translation in Immuno-Oncology Research and Development. <b>2020</b> , 108, 430-433	0
819	Immunotherapy for Non-small Cell Lung Cancer: Current Landscape and Future Perspectives. <b>2020</b> , 20, e10	51
818	Photodynamic Therapy and Immune Checkpoint Blockade. <b>2020</b> , 96, 954-961	20
817	Immune-Related Pneumonitis After Chemoradiotherapy and Subsequent Immune Checkpoint Blockade in Unresectable Stage III Non-Small-Cell Lung Cancer. <b>2020</b> , 21, e435-e444	21
816	Combination of Ipilimumab and Nivolumab in Cancers: From Clinical Practice to Ongoing Clinical Trials. <b>2020</b> , 21,	28
815	Balancing Cancer Immunotherapy Efficacy and Toxicity. <b>2020</b> , 8, 2898-2906	14
814	How to Monitor Cardiac Complications of Immune Checkpoint Inhibitor Therapy. <b>2020</b> , 11, 972	11
813	Integrating the Tumor Microenvironment into Cancer Therapy. <b>2020</b> , 12,	13
812	Axitinib plus immune checkpoint inhibitor: evidence- and expert-based consensus recommendation for treatment optimisation and management of related adverse events. <b>2020</b> , 123, 898-904	14
811	Advances in Anti-Cancer Immunotherapy: Car-T Cell, Checkpoint Inhibitors, Dendritic Cell Vaccines, and Oncolytic Viruses, and Emerging Cellular and Molecular Targets. <b>2020</b> , 12,	20
810	Immune checkpoint inhibitors in women with gynecologic cancers: Practical considerations. <b>2020</b> , 158, 531-537	4
809	Pembrolizumab-induced Hemophagocytic Lymphohistiocytosis: an immunotherapeutic challenge. <b>2020</b> , 5, 3	11
808	Immune-mediated adverse effects of immune-checkpoint inhibitors and their management in cancer. <b>2020</b> , 221, 61-71	5
807	Immune checkpoint inhibitor-associated interstitial lung diseases correlate with better prognosis in patients with advanced non-small-cell lung cancer. <b>2020</b> , 11, 1052-1060	22
806	Cardiac Adverse Events Related to Immune Checkpoint Inhibitors. <b>2020</b> , 2, 200-202	1
805	Recognition and management of the gastrointestinal and hepatic immune-related adverse events. <b>2020</b> , 16, 95-102	3
804	Prevention Strategies to Minimize the Infection Risk Associated with Biologic and Targeted Immunomodulators. <b>2020</b> , 13, 513-532	4

803	Checkpoint Inhibitor-Induced Colitis. <b>2020</b> , 115, 202-210	28
802	Severe Neurological Toxicity of Immune Checkpoint Inhibitors: Growing Spectrum. <b>2020</b> , 87, 659-669	67
801	[Novel cancer treatment and the cardiovascular risk : What should cardiologists know?]. <b>2020</b> , 45, 129-133	
800	A new immunotherapy schedule in addition to first-line hormone therapy for metastatic breast cancer patients in a state of clinical benefit during hormone therapy. <b>2020</b> , 98, 375-382	2
799	Atypical Presentations and Management of Endocrine and Hepatic Immune-Related Adverse Events From Adjuvant Immune Checkpoint Inhibitor Therapy in Stage III Resected Melanoma. <b>2020</b> , 16, 10s-14s	0
798	Endocrine-Related Adverse Events Related to Immune Checkpoint Inhibitors: Proposed Algorithms for Management. <b>2020</b> , 25, 290-300	28
797	A review of cancer immunotherapy toxicity. <b>2020</b> , 70, 86-104	304
796	Management of cardiac disease in cancer patients throughout oncological treatment: ESMO consensus recommendations. <b>2020</b> , 31, 171-190	262
795	Toxicity of Immune Checkpoint Inhibitors: Considerations for the Surgeon. <b>2020</b> , 27, 1533-1545	4
794	Health-related quality of life in cancer patients treated with immune checkpoint inhibitors: A systematic review on reporting of methods in randomized controlled trials. <b>2020</b> , 15, e0227344	13
793	Diagnosis and management of toxicities of immune checkpoint inhibitors in hepatocellular carcinoma. <b>2020</b> , 72, 320-341	68
792	Possibilities of Improving the Clinical Value of Immune Checkpoint Inhibitor Therapies in Cancer Care by Optimizing Patient Selection. <b>2020</b> , 21,	11
791	Immunotherapy Approaches for Pediatric CNS Tumors and Associated Neurotoxicity. <b>2020</b> , 107, 7-15	2
790	Management of Patients With Immune Checkpoint Inhibitor-Induced Enterocolitis: A Systematic Review. <b>2020</b> , 18, 1393-1403.e1	15
789	Immunotherapy and Targeted Drugs for Common Cancers. <b>2020</b> , 16, 195-200	
788	The immunopathogenesis of rheumatic immune adverse events from checkpoint inhibitors: prospects for targeted therapy. <b>2020</b> , 32, 175-183	1
787	Neurotoxicities associated with checkpoint inhibitors: Two case reports and a review of the literature. <b>2020</b> , 8, 24-32	5
786	Sub-acute Toxicity in Non-cancerous Tissue and Immune-Related Adverse Events of a Novel Combination Therapy for Cancer. <b>2019</b> , 9, 1504	3

785	Toxicity management with combination chemotherapy and programmed death 1/programmed death ligand 1 inhibitor therapy in advanced lung cancer. <b>2020</b> , 85, 101979	14
784	A review of the imaging manifestations of immune check point inhibitor toxicities. <b>2020</b> , 64, 70-79	3
783	Überblick Nebenwirkungsmanagement moderner Immuntherapien. <b>2020</b> , 53, 244-250	0
782	Characterization of risk factors and efficacy of medical management of immune-related hepatotoxicity in real-world patients with metastatic melanoma treated with immune checkpoint inhibitors. <b>2020</b> , 130, 211-218	10
781	Central diabetes insipidus related to anti-programmed cell-death 1 protein active immunotherapy. <b>2020</b> , 83, 106427	14
780	Autoimmune complications of immunotherapy: pathophysiology and management. <b>2020</b> , 369, m736	39
779	Conditional immune toxicity rate in patients with metastatic renal and urothelial cancer treated with immune checkpoint inhibitors. <b>2020</b> , 8,	8
778	Public Adverse Event Data Insights into the Safety of Pembrolizumab in Melanoma Patients. <b>2020</b> , 12,	0
777	Diffuse large B-cell lymphoma after nivolumab treatment for lung cancer: A case report and a World Health Organization pharmacovigilance database review. <b>2020</b> , 130, 20-22	0
776	An update on the safety of nivolumab for the treatment of advanced melanoma. <b>2020</b> , 19, 409-421	4
775	Description and Proposed Management of the Acute COVID-19 Cardiovascular Syndrome. <b>2020</b> , 141, 1903-1914	302
774	Immune Checkpoint Inhibitor Rechallenge After Immune-Related Adverse Events in Patients With Cancer. <b>2020</b> , 6, 865-871	126
773	Moderate-to-severe eosinophilia induced by treatment with immune checkpoint inhibitors: 37 cases from a national reference center for hypereosinophilic syndromes and the French pharmacovigilance database. <b>2020</b> , 9, 1722022	12
772	Management Considerations for Immune Checkpoint Inhibitor-Induced Enterocolitis Based on Management of Inflammatory Bowel Disease. <b>2020</b> , 26, 662-668	7
771	Mechanism-based treatment of cancer with immune checkpoint inhibitor therapies. <b>2020</b> , 86, 1690-1702	13
770	Safety and efficacy of restarting immune checkpoint inhibitors after clinically significant immune-related adverse events in metastatic renal cell carcinoma. <b>2020</b> , 8,	35
769	Insights from immuno-oncology: the Society for Immunotherapy of Cancer Statement on access to IL-6-targeting therapies for COVID-19. <b>2020</b> , 8,	42
768	Combination Immunotherapy with Cytotoxic T-Lymphocyte-Associated Antigen-4 and Programmed Death Protein-1 Inhibitors Prevents Postoperative Breast Tumor Recurrence and Metastasis. <b>2020</b> , 19, 802-811	8

767	Reply to Y. Inagaki et al. <b>2020</b> , 38, 1749-1750	0
766	Immunotherapy in Metastatic Colorectal Cancer: Could the Latest Developments Hold the Key to Improving Patient Survival?. <b>2020</b> , 12,	11
765	EULAR points to consider for the diagnosis and management of rheumatic immune-related adverse events due to cancer immunotherapy with checkpoint inhibitors. <b>2021</b> , 80, 36-48	61
764	Diabetes mellitus induced by immune checkpoint inhibitors. <b>2021</b> , 37, e3366	4
763	Vitamin D, autoimmunity and immune-related adverse events of immune checkpoint inhibitors. <b>2021</b> , 313, 1-10	8
762	PD-1/PD-L1 immune checkpoint inhibitors in glioblastoma: clinical studies, challenges and potential. <b>2021</b> , 17, 546-553	10
761	Successful Treatment of an Immune-Mediated Colitis Induced by Checkpoint Inhibitor Therapy in a Patient with Advanced Melanoma. <b>2020</b> , 14, 554-560	1
760	Advances on immune-related adverse events associated with immune checkpoint inhibitors. <b>2021</b> , 15, 33-42	14
759	Impact of histamine H4 receptor deficiency on the modulation of T cells in a murine breast cancer model. <b>2021</b> , 70, 233-244	5
758	New onset diabetes with ketoacidosis following nivolumab immunotherapy: A case report and review of literature. <b>2021</b> , 27, 716-721	5
757	Immunotherapy for older patients with melanoma: From darkness to light?. <b>2021</b> , 34, 550-563	2
756	Treatment of rheumatic immune-related adverse events due to cancer immunotherapy with immune checkpoint inhibitors-is it time for a paradigm shift?. <b>2021</b> , 40, 1687-1695	5
755	Asymptomatic brainstem lesions and pachymeningeal enhancement after anti-PD-1 therapy. <b>2021</b> , 13, 11-17	0
754	Clinical Outcomes of Patients with Metastatic Cancer Receiving Immune Checkpoint Inhibitors in the Inpatient Setting. <b>2021</b> , 26, 49-55	9
753	AGA Clinical Practice Update on Diagnosis and Management of Immune Checkpoint Inhibitor Colitis and Hepatitis: Expert Review. <b>2021</b> , 160, 1384-1393	31
752	Neoadjuvant immune checkpoint inhibitors in cancer, current state of the art. <b>2021</b> , 157, 103172	2
751	Toxicities Associated with Immunotherapy and Approach to Cardiotoxicity with Novel Cancer Therapies. <b>2021</b> , 37, 47-67	2
750	Expert Perspective: Immune Checkpoint Inhibitors and Rheumatologic Complications. <b>2021</b> , 73, 553-565	6

749	The application of nano-medicine to overcome the challenges related to immune checkpoint blockades in cancer immunotherapy: Recent advances and opportunities. <b>2021</b> , 157, 103160	11
748	Clinical characteristics and management of immune checkpoint inhibitor-related pneumonitis: A single-institution retrospective study. <b>2021</b> , 10, 188-198	6
747	Poly(anhydride-ester) gemcitabine: Synthesis and particle engineering of a high payload hydrolysable polymeric drug for cancer therapy. <b>2021</b> , 330, 1178-1190	2
746	Neurologic Complications of Immune Checkpoint Inhibitors in Thoracic Malignancies. <b>2021</b> , 16, 381-394	7
745	The risk of cardiac events in patients receiving immune checkpoint inhibitors: a nationwide Danish study. <b>2021</b> , 42, 1621-1631	37
744	Multifocal Tendon Ruptures during Nivolumab and Ipilimumab Therapy for Metastatic Melanoma: A Case Report. <b>2020</b> ,	0
743	Cost-effectiveness of nivolumab in advanced melanoma: a drug review. <b>2021</b> , 21, 13-28	
742	Renal cell carcinoma with central nervous system demyelination caused by nivolumab. <b>2021</b> , 4, 44-48	
741	Abdominal immune-related adverse events: detection on ultrasonography, CT, MRI and 18F-Fluorodeoxyglucose positron emission tomography. <b>2021</b> , 94, 20200663	1
740	Immune Checkpoint Inhibitor-associated Uveitis: Review of Treatments and Outcomes. <b>2021</b> , 29, 203-211	15
739	Clinical Pharmacology and Interplay of Immune Checkpoint Agents: A Yin-Yang Balance. <b>2021</b> , 61, 85-112	17
738	Magnifying endoscopy with crystal violet staining for immune checkpoint inhibitor-associated colitis. <b>2021</b> , 36, 1180-1186	0
737	Autoimmune Endocrinopathies: An Emerging Complication of Immune Checkpoint Inhibitors. <b>2021</b> , 72, 313-330	11
736	Evaluation of emergency departments visits in patients treated with immune checkpoint inhibitors. <b>2021</b> , 29, 2029-2035	4
735	The Role of the Pharmacist in Optimizing Cancer Immunotherapy: A Retrospective Study of Nivolumab Adverse Events. <b>2021</b> , 34, 386-396	2
734	Practical Management of Melanoma. <b>2021</b> , 241-256	
733	Neurologic Complications of Chemotherapy and Radiation Therapy. <b>2021</b> , 521-537	
732	Immune-Related Adverse Events with Immune Checkpoint Inhibitors: Polymyalgia Rheumatica. <b>2021</b> , 89-98	

731	Cancer Immunotherapy in Patients with Preexisting Rheumatic Diseases: Other Rheumatic Autoimmune Diseases. <b>2021</b> , 293-306	
730	Management of Rheumatic Immune-Related Adverse Events (irAEs): General Principles. <b>2021</b> , 309-321	
729	Immunotherapy-related toxicity in lung cancer: clinical characteristics and managing strategy. <b>2021</b> , 134, 780-782	0
728	Efficacy and side effects of immune checkpoint inhibitors in the treatment of colorectal cancer. <b>2021</b> , 14, 17562848211002018	1
727	Immunotherapy-induced pneumonitis in non-small cell lung cancer patients: current concern in treatment with immune-check-point inhibitors. <b>2021</b> , 39, 891-898	2
726	GI Toxicities from Cancer Therapy. <b>2021</b> , 341-379	
725	Immune manifestations with checkpoint inhibitors in a single Brazilian center: experience and literature review. <b>2020</b> , 7, FSO655	1
724	Critical Analysis of Immune Checkpoint Inhibitor Immunotoxicity Management. <b>2021</b> , 3, 84-94	
723	Organ-specific Adverse Events of Immune Checkpoint Inhibitor Therapy, with Special Reference to Endocrinopathies. <b>2021</b> , 1, 21	
722	From biomarkers to therapeutic targets: the promise of PD-L1 in thyroid autoimmunity and cancer. <b>2021</b> , 11, 1310-1325	11
721	The Role of Immunotherapy in the Treatment of Adrenocortical Carcinoma. <b>2021</b> , 9,	4
720	Steroid-refractory PD-(L)1 pneumonitis: incidence, clinical features, treatment, and outcomes. <b>2021</b> , 9,	12
719	Cytokine changes during immune-related adverse events and corticosteroid treatment in melanoma patients receiving immune checkpoint inhibitors. <b>2021</b> , 70, 2209-2221	11
718	Paraneoplastic neurological syndromes: clinical presentations and management. <b>2021</b> , 14, 175628642098532311	
717	Inflammatory pituitary lesions. <b>2021</b> , 575-589	
716	Immunotherapy in hepatocellular carcinoma: evaluation and management of adverse events associated with atezolizumab plus bevacizumab. <b>2021</b> , 13, 17588359211031141	4
715	Immune Checkpoint Inhibitors in Special Populations. <b>2021</b> , 20, 15330338211036526	
714	Organ-specific Adverse Events of Immune Checkpoint Inhibitor Therapy, with Special Reference to Endocrinopathies. <b>2021</b> , 1, 21	1

713	Immune checkpoint inhibitors-related myocarditis in patients with cancer: an analysis of international spontaneous reporting systems. <b>2021</b> , 21, 38	3
712	Diarrhea. <b>2021</b> , 357-365	
711	Neurological Complications of Cancer Therapies. <b>2021</b> , 133-144	
710	Immunotherapy for Metastatic Urothelial Carcinoma. <b>2021</b> , 305-313	
709	Sarcoidosis-like reactions in cancer patients treated with immune checkpoint inhibitors: experience in a Spanish hospital. <b>2021</b> , 23, 1474-1480	2
708	A Machine Learning-Aided Framework to Predict Outcomes of Anti-PD-1 Therapy for Patients With Gynecological Cancer on Incomplete Post-Marketing Surveillance Dataset. <b>2021</b> , 9, 120464-120480	1
707	Immune-Related Adverse Events in the Older Adult with Cancer Receiving Immune Checkpoint Inhibitor Therapy. <b>2021</b> , 8, 18-24	1
706	Autoimmune encephalopathies presenting as dementia of subacute onset and rapid progression. <b>2021</b> , 14, 1756286421998906	4
705	Surgery after neoadjuvant immunotherapy in patients with resectable non-small cell lung cancer. <b>2021</b> , 10, 563-580	6
704	Severe colitis induced by pembrolizumab in a patient with advanced hypopharyngeal squamous cell carcinoma: A case report of an immune-related adverse event. <b>2021</b> , 8, 113	0
703	Real Impact of Novel Immunotherapy Drugs in Cancer. The Experience of 10 Last Years. <b>2021</b> , 13,	3
702	Personalized Cytokine-Directed Therapy With Tocilizumab for Refractory Immune Checkpoint Inhibitor-Related Cholangiohepatitis. <b>2021</b> , 16, 318-326	7
701	The Efficacy and Safety of Immune Checkpoint Inhibitors in Patients With Cancer and Preexisting Autoimmune Disease. <b>2021</b> , 11, 625872	4
700	Paraneoplastic neurological syndrome: an evolving story. <b>2021</b> , 8, 362-374	
699	Long-term safety of pembrolizumab monotherapy and relationship with clinical outcome: A landmark analysis in patients with advanced melanoma. <b>2021</b> , 144, 182-191	23
698	Status of Metastatic Bladder Cancer Treatment Illustrated by a Case. <b>2021</b> , 37, 151113	0
697	Clock at the Core of Cancer Development. <b>2021</b> , 10,	2
696	CAR-T and checkpoint inhibitors: toxicities and antidotes in the emergency department. <b>2021</b> , 59, 376-385	1



695	Real-world insights on preferred treatments for steroid-refractory immune checkpoint inhibitor-induced pneumonitis. <b>2021</b> , 9,	
694	Success and failure of additional immune modulators in steroid-refractory/resistant pneumonitis related to immune checkpoint blockade. <b>2021</b> , 9,	3
693	Harnessing Tumor Necrosis Factor Alpha to Achieve Effective Cancer Immunotherapy. <b>2021</b> , 13,	14
692	Combined anti-PD-1 and anti-CTLA-4 checkpoint blockade: Treatment of melanoma and immune mechanisms of action. <b>2021</b> , 51, 544-556	13
691	Therapeutic potential of bicyclol in liver diseases: Lessons from a synthetic drug based on herbal derivative in traditional Chinese medicine. <b>2021</b> , 91, 107308	8
690	Role of gut microbiome in the outcome of cancer immunotherapy. <b>2021</b> , 149, 760	3
689	Attitudes and Practices of Immune Checkpoint Inhibitors in Chinese Patients With Cancer: A National Cross-Sectional Survey. <b>2021</b> , 12, 583126	1
688	Newly diagnosed cardiovascular disease in patients treated with immune checkpoint inhibitors: a retrospective analysis of patients at an academic tertiary care center. <b>2021</b> , 7, 10	3
687	Prediction of severe immune-related adverse events requiring hospital admission in patients on immune checkpoint inhibitors: study of a population level insurance claims database from the USA. <b>2021</b> , 9,	6
686	Rethinking the management of immune checkpoint inhibitor-related adrenal insufficiency in cancer patients during the COVID-19 pandemic. <b>2021</b> , 4, e00246	1
685	Considerations for treatment duration in responders to immune checkpoint inhibitors. <b>2021</b> , 9,	13
684	Immune-related adverse events and immune checkpoint inhibitor tolerance on rechallenge in patients with irAEs: a single-center experience. <b>2021</b> , 147, 2789-2800	5
683	Immuno-oncology: a narrative review of gastrointestinal and hepatic toxicities. <b>2021</b> , 9, 423	1
682	Checkpoint blockade toxicities: Insights into autoimmunity and treatment. <b>2021</b> , 52, 101473	3
681	Pharmacological Interventions for the Prevention and Treatment of Immune Checkpoint Inhibitor-Associated Enterocolitis: A Systematic Review. <b>2021</b> , 1	0
680	Is There a Place for PD-1-PD-L Blockade in Acute Myeloid Leukemia?. <b>2021</b> , 14,	5
679	Immune checkpoint inhibitor toxicity: A new indication for therapeutic plasma exchange?. <b>2021</b> , 36, 645-648	2
678	A novel immuno-oncology algorithm measuring tumor microenvironment to predict response to immunotherapies. <b>2021</b> , 7, e06438	5

677	The Immune Checkpoint Inhibitor LAG-3 and Its Ligand GAL-3 in Vulvar Squamous Neoplasia. <b>2021</b> ,	2
676	Steroid-refractory dermatologic and pulmonary toxicity in a patient on rituximab treated with pembrolizumab for progressive urothelial carcinoma: a case report. <b>2021</b> , 15, 124	3
675	Extending the conversation over the immune-related hepatotoxicity: author response to Dr. Gauci. <b>2021</b> , 9,	1
674	Chest CT Diagnosis and Clinical Management of Drug-related Pneumonitis in Patients Receiving Molecular Targeting Agents and Immune Checkpoint Inhibitors: A Position Paper from the Fleischner Society. <b>2021</b> , 298, 550-566	15
673	Bayesian interval-based oncology dose-finding design with repeated quasi-continuous toxicity model. <b>2021</b> , 102, 106265	
672	Supportive care for new cancer therapies. <b>2021</b> , 33, 287-294	2
671	Immune checkpoint inhibitor-associated myocarditis: manifestations and mechanisms. <b>2021</b> , 131,	19
670	An Evaluation of the Use of Corticosteroids for the Management of Immune-Mediated Adverse Events in Cancer Patients Treated With Immune Checkpoint Inhibitors. <b>2021</b> , 12, 137-145	1
669	Recurrent Myocarditis Induced by Immune-Checkpoint Inhibitor Treatment Is Accompanied by Persistent Inflammatory Markers Despite Immunosuppressive Treatment. <b>2021</b> , 5,	4
668	Chest CT Diagnosis and Clinical Management of Drug-Related Pneumonitis in Patients Receiving Molecular Targeting Agents and Immune Checkpoint Inhibitors: A Position Paper From the Fleischner Society. <b>2021</b> , 159, 1107-1125	15
667	Treatment of corticosteroid refractory immune checkpoint inhibitor myocarditis with Infliximab: a case series. <b>2021</b> , 7, 13	6
666	Evaluation of a Multidisciplinary Immunotherapy Toxicity Monitoring Program for Patients Receiving Ipilimumab for Metastatic Melanoma. <b>2021</b> , 17, e1631-e1638	1
665	Cryoablation and Immunotherapy for Breast Cancer: Overview and Rationale for Combined Therapy. <b>2021</b> , 3, e200134	3
664	Immunotherapy in Adrenocortical Carcinoma: Predictors of Response, Efficacy, Safety, and Mechanisms of Resistance. <b>2021</b> , 9,	6
663	Systemic adverse effects and toxicities associated with immunotherapy: A review. <b>2021</b> , 12, 150-163	7
662	Recognizing encephalopathy in immune checkpoint inhibitor therapy: A single-center experience. <b>2021</b> , 10, 2978-2986	0
661	Open-Label, Single-Arm Phase II Study of Pembrolizumab Monotherapy as First-Line Therapy in Patients With Advanced Clear Cell Renal Cell Carcinoma. <b>2021</b> , 39, 1020-1028	26
660	Clinical Characteristics, Management, and Potential Biomarkers of Endocrine Dysfunction Induced by Immune Checkpoint Inhibitors. <b>2021</b> , 36, 312-321	4

659	The Role of Systemic Therapy in Advanced Cutaneous Melanoma of the Head and Neck. <b>2021</b> , 54, 329-342	
658	Epidemiology and risk factors for the development of cutaneous toxicities in patients treated with immune-checkpoint inhibitors: A United States population-level analysis. <b>2021</b> ,	12
657	Imaging spectrum of adverse events of immune checkpoint inhibitors. <b>2021</b> , 76, 262-272	2
656	A Review of Cancer Immunotherapy Toxicity: Immune Checkpoint Inhibitors. <b>2021</b> , 17, 411-424	11
655	How can we manage the cardiac toxicity of immune checkpoint inhibitors?. <b>2021</b> , 20, 685-694	5
654	Development of Vogt-Koyanagi-Harada Disease-like Uveitis during Treatment by Anti-programmed Death Ligand-1 Antibody for Non-small Cell Lung Cancer: A Case Report. <b>2021</b> , 1-5	1
653	Radiomics analysis for predicting pembrolizumab response in patients with advanced rare cancers. <b>2021</b> , 9,	11
652	Hypophysitis related to immune checkpoint inhibitors: An intriguing adverse event with many faces. <b>2021</b> , 21, 1097-1120	1
651	Paraneoplastic Neurological Syndromes and Beyond Emerging With the Introduction of Immune Checkpoint Inhibitor Cancer Immunotherapy. <b>2021</b> , 12, 642800	9
650	Penfigoide ampollar en paciente en tratamiento con nivolumab. <b>2021</b> , 36, 224-226	
649	Cancer Therapy-Related Cardiovascular Complications in Clinical Practice: Current Perspectives. <b>2021</b> , 10,	3
648	Gastrointestinal disorders as immune-related adverse events.	
647	Rapid corticosteroid taper versus standard of care for immune checkpoint inhibitor induced nephritis: a single-center retrospective cohort study. <b>2021</b> , 9,	10
646	Endocrine toxicities of immune checkpoint inhibitors. <b>2021</b> , 17, 389-399	30
645	Immune checkpoint inhibitors for treatment of small-cell lung cancer: a systematic review and meta-analysis. <b>2021</b> , 9, 705	3
644	IL-6 modulation for COVID-19: the right patients at the right time?. <b>2021</b> , 9,	12
643	Inflammatory markers in autoimmunity induced by checkpoint inhibitors. <b>2021</b> , 147, 1623-1630	9
642	Encephalitis Associated With Immune Checkpoint Inhibitor Treatment in Patients With Melanoma. <b>2021</b> , 44, 204-207	1

641	Expected and non-expected immune-related adverse events detectable by CT. <b>2021</b> , 138, 109617	
640	Late-onset and long-lasting immune-related adverse events from immune checkpoint-inhibitors: An overlooked aspect in immunotherapy. <b>2021</b> , 149, 153-164	15
639	Neuro-Oncologic Emergencies. <b>2021</b> , 39, 545-563	2
638	Granulomatous colitis in a patient with metastatic melanoma under immunotherapy: a case report and literature review. <b>2021</b> , 21, 227	2
637	What the Cardiologist Needs to Know About Cancer Immunotherapies and Complications. <b>2021</b> , 22, 53	0
636	Clinical implications of bronchoscopy for immune checkpoint inhibitor-related pneumonitis in patients with non-small cell lung cancer. <b>2021</b> , 21, 155	2
635	Immunotherapy-Induced Acute Tubulointerstitial Nephritis. <b>2021</b> , 13, e15358	
634	Immune Checkpoint Inhibitor-Associated Pneumonitis in Non-Small Cell Lung Cancer: Current Understanding in Characteristics, Diagnosis, and Management. <b>2021</b> , 12, 663986	6
633	Molecular and Clinical Features of Hospital Admissions in Patients with Thoracic Malignancies on Immune Checkpoint Inhibitors. <b>2021</b> , 13,	
632	The Impact of Adverse Events on Health Care Resource Utilization, Costs, and Mortality Among Patients Treated with Immune Checkpoint Inhibitors. <b>2021</b> , 26, e1205-e1215	2
631	Immunotherapy in Treating EGFR-Mutant Lung Cancer: Current Challenges and New Strategies. <b>2021</b> , 11, 635007	19
630	Management of adverse events in cancer treatment with immune checkpoint inhibitors. <b>2021</b> , 64, 358-365	
629	Cardiotoxicity of immune checkpoint inhibitors: A systematic review and meta-analysis of randomised clinical trials. <b>2021</b> , 148, 76-91	10
628	Histopathology of Gastrointestinal Immune-related Adverse Events: A Practical Review for the Practicing Pathologist. <b>2022</b> , 46, e15-e26	0
627	Combining anti-cytotoxic T-lymphocyte antigen 4 (CTLA-4) and -programmed cell death protein 1 (PD-1) agents for cancer immunotherapy. <b>2021</b> , 21, 1623-1634	2
626	A retrospective analysis of cardiovascular adverse events associated with immune checkpoint inhibitors. <b>2021</b> , 7, 19	4
625	Avelumab first-line maintenance in locally advanced or metastatic urothelial carcinoma: Applying clinical trial findings to clinical practice. <b>2021</b> , 97, 102187	9
624	Post-immunotherapy imaging in lung cancer. <b>2021</b> ,	1

623	Endocrine Toxicity and Outcomes in Patients With Metastatic Malignancies Treated With Immune Checkpoint Inhibitors. <b>2021</b> , 5, bvab100	3
622	Safe anti-programmed cell death-1 rechallenge with antibody switching after immune-related adverse events: brief communication. <b>2021</b> , 13, 745-752	0
621	Immune Checkpoint Inhibitors-Related Thyroid Dysfunction: Epidemiology, Clinical Presentation, Possible Pathogenesis, and Management. <b>2021</b> , 12, 649863	7
620	Outcomes of Immune Checkpoint Inhibitor-related Diarrhea or Colitis in Cancer Patients With Superimposed Gastrointestinal Infections. <b>2021</b> , 44, 402-408	2
619	Exploiting the obesity-associated immune microenvironment for cancer therapeutics. <b>2021</b> , 229, 107923	1
618	Immune-related cutaneous adverse events due to checkpoint inhibitors. <b>2021</b> , 126, 613-622	2
617	Managing side effects of immune checkpoint inhibitors in breast cancer. <b>2021</b> , 162, 103354	6
616	Meta-analysis of immune-related adverse events in phase 3 clinical trials assessing immune checkpoint inhibitors for lung cancer. <b>2021</b> , 162, 103351	8
615	Inhibition of Polyamine Biosynthesis Using Difluoromethylornithine Acts as a Potent Immune Modulator and Displays Therapeutic Synergy With PD-1-blockade. <b>2021</b> , 44, 283-291	1
614	Bibliometric Analysis of Clinical Decision Support Systems. <b>2021</b> , 10, 61-74	1
613	The Tumor Microenvironment Factors That Promote Resistance to Immune Checkpoint Blockade Therapy. <b>2021</b> , 11, 641428	8
612	Clinical characteristics, time course, treatment and outcomes of patients with immune checkpoint inhibitor-associated myocarditis. <b>2021</b> , 9,	2
611	Spontaneous and Immune Checkpoint Inhibitor-Induced Autoimmune Diseases: Analysis of Temporal Information by Using the Japanese Adverse Drug Event Report Database. <b>2021</b> , 41, 615-627	0
610	Cutaneous Toxicities in the Setting of Immune Checkpoint Blockade:: The Era of Oncodermatopathology. <b>2021</b> , 14, 209-224	0
609	Immune checkpoint inhibitor combination therapies very frequently induce secondary adrenal insufficiency. <b>2021</b> , 11, 11617	1
608	Managing toxicities associated with immune checkpoint inhibitors. <b>2021</b> , 34, 32-39	0
607	Guidelines for clinical evaluation of anti-cancer drugs. <b>2021</b> , 112, 2563-2577	5
606	The knowns & unknowns of pulmonary toxicity following immune checkpoint inhibitor therapies: a narrative review. <b>2021</b> , 10, 2752-2765	1

605	Efficacy and Safety of Anti-PD-1/ PD-L1 Monotherapy for Metastatic Breast Cancer: Clinical Evidence. <b>2021</b> , 12, 653521	1
604	Immune Checkpoint Inhibition in Advanced Bladder and Kidney Cancer: Responses and Further Management. <b>2021</b> , 41, e182-e189	1
603	Late-onset adverse events of anti-PD1 therapy in melanoma patients: An observational study from MELBASE, a nationwide prospective cohort. <b>2021</b> ,	0
602	Frequency, Treatment and Outcome of Immune-Related Toxicities in Patients with Immune-Checkpoint Inhibitors for Advanced Melanoma: Results from an Institutional Database Analysis. <b>2021</b> , 13,	5
601	Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune checkpoint inhibitor-related adverse events. <b>2021</b> , 9,	58
600	Pericardial disease in patients treated with immune checkpoint inhibitors. <b>2021</b> , 9,	2
599	Antibody-drug conjugates, immune-checkpoint inhibitors, and their combination in breast cancer therapeutics. <b>2021</b> , 21, 945-962	4
598	Perspectives on interstitial photodynamic therapy for malignant tumors. <b>2021</b> , 26,	2
597	Presumed complement-mediated, checkpoint inhibitor-induced, thrombotic microangiopathy in a patient with metastatic melanoma. <b>2021</b> , 14,	2
596	Peripheral Blood Biomarkers for Early Diagnosis, Severity, and Prognosis of Checkpoint Inhibitor-Related Pneumonitis in Patients With Lung Cancer. <b>2021</b> , 11, 698832	3
595	Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of urothelial cancer. <b>2021</b> , 9,	2
594	CX-072 (pacmilimab), a Probody PD-L1 inhibitor, in advanced or recurrent solid tumors (PROCLAIM-CX-072): an open-label dose-finding and first-in-human study. <b>2021</b> , 9,	5
593	Consensus disease definitions for neurologic immune-related adverse events of immune checkpoint inhibitors. <b>2021</b> , 9,	20
592	Hepatozelluläres Karzinom. <b>2021</b> , 2, 47-55	
591	Immune-related toxicities of checkpoint inhibitors: mechanisms and mitigation strategies. <b>2021</b> ,	26
590	Prediction of Early Response to Immune Checkpoint Inhibition Using FDG-PET/CT in Melanoma Patients. <b>2021</b> , 13,	4
589	Association of Immune-Related Adverse Events and Efficacy Outcomes With Consolidation Pembrolizumab After Chemoradiation in Patients With Inoperable Stage III Non-Small-Cell Lung Cancer. <b>2021</b> , 22, 274-281	0
588	Myositis and myasteniform syndrome related to pembrolizumab. <b>2021</b> , 14,	2

587	Immunotherapy-Related Cystitis: Case Report and Review of the Literature. <b>2021</b> , 14, 4321-4328	3
586	Clinical Course and Treatment Implications of Combination Immune Checkpoint Inhibitor-Mediated Hepatitis: A Multicentre Cohort.. <b>2022</b> , 5, 39-47	2
585	Management of PD-1/PD-L1 blockade immune-related skin toxicities: perspectives and issues. <b>2021</b> , 13, 795-798	
584	Immune checkpoint inhibitor related hypophysitis: diagnostic criteria and recovery patterns. <b>2021</b> , 28, 419-431	11
583	Pembrolizumab monotherapy for the treatment of high-risk non-muscle-invasive bladder cancer unresponsive to BCG (KEYNOTE-057): an open-label, single-arm, multicentre, phase 2 study. <b>2021</b> , 22, 919-930	53
582	CX-072 (pacmilimab), a Probody PD-L1 inhibitor, in combination with ipilimumab in patients with advanced solid tumors (PROCLAIM-CX-072): a first-in-human, dose-finding study. <b>2021</b> , 9,	5
581	Mechanisms Driving Immune-Related Adverse Events in Cancer Patients Treated with Immune Checkpoint Inhibitors. <b>2021</b> , 23, 98	9
580	Immune-related adverse events associated with immune checkpoint inhibitors: a call to action for collecting and sharing clinical trial and real-world data. <b>2021</b> , 9,	7
579	First-in-human phase 1 study of budigalimab, an anti-PD-1 inhibitor, in patients with non-small cell lung cancer and head and neck squamous cell carcinoma. <b>2021</b> , 1	1
578	New systemic therapies for cutaneous melanoma: why, who and what. <b>2021</b> , 156, 344-355	2
577	Complete pathological response with diabetic ketoacidosis to the combination of sintilimab and anlotinib in an unresectable hepatocellular carcinoma patient: a case report. <b>2021</b> ,	3
576	Timing of steroid initiation and response rates to immune checkpoint inhibitors in metastatic cancer. <b>2021</b> , 9,	9
575	Management and Clinical Outcome of Posterior Reversible Encephalopathy Syndrome in Pediatric Oncologic/Hematologic Diseases: A PRES Subgroup Analysis With a Large Sample Size. <b>2021</b> , 9, 678890	0
574	Toxicity of Immunotherapeutic Agents. <b>2021</b> , 37, 605-624	1
573	Immune checkpoint inhibitor induced colitis: A nationwide population-based study. <b>2021</b> , 46, 101778	0
572	Medikamentö-toxische Leberschädigung und Immuncheckpointinhibitor-induzierte Hepatitis. <b>2021</b> , 19, 34-43	
571	Inhibitors of immune checkpoints-PD-1, PD-L1, CTLA-4-new opportunities for cancer patients and a new challenge for internists and general practitioners. <b>2021</b> , 40, 949-982	17
570	Non-invasive Detection of Immunotherapy-Induced Adverse Events. <b>2021</b> ,	3

569	Case Report: Dual Checkpoint Inhibition in Advanced Metastatic Osteosarcoma Results in Remission of All Tumor Manifestations-A Report of a Stunning Success in a 37-Year-Old Patient. <b>2021</b> , 11, 684733	2
568	Clinical implications of isolated troponinemia following immune checkpoint inhibitor therapy. <b>2021</b> , 6, 100216	5
567	Lung cancer. <b>2021</b> , 398, 535-554	115
566	Systemic Treatment of Cutaneous Adverse Events After Immune Checkpoint Inhibitor Therapy: A Review. <b>2021</b> ,	0
565	Multifunctional Nanocarriers-Mediated Synergistic Combination of Immune Checkpoint Inhibitor Cancer Immunotherapy and Interventional Oncology Therapy. <b>2021</b> , 1, 2100010	2
564	What do Emergency Physicians Know About Immune Checkpoint Inhibitor-Related Toxicities: A Brief Report. <b>2021</b> , 14,	0
563	Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of breast cancer. <b>2021</b> , 9,	7
562	Evaluation of Technology-Enabled Monitoring of Patient-Reported Outcomes to Detect and Treat Toxic Effects Linked to Immune Checkpoint Inhibitors. <b>2021</b> , 4, e2122998	2
561	Oral manifestations of immune-related adverse events in cancer patients treated with immune checkpoint inhibitors. <b>2021</b> ,	3
560	Liver Injury and Use of Contrast-Enhanced Ultrasound for Evaluating Intrahepatic Recurrence in a Case of TACE-Refractory Hepatocellular Carcinoma Receiving Atezolizumab-Bevacizumab Combination Therapy: A Case Report. <b>2021</b> , 11,	0
559	Clinicopathologic Features, Treatment Response, and Outcomes of Immune Checkpoint Inhibitor-Related Esophagitis. <b>2021</b> , 19, 896-904	2
558	Immune checkpoint inhibitor-mediated colitis in gastrointestinal malignancies and inflammatory bowel disease. <b>2021</b> , 13, 772-798	2
557	Sargramostim and immune checkpoint inhibitors: combinatorial therapeutic studies in metastatic melanoma. <b>2021</b> , 13, 1011-1029	1
556	Emergency Presentations of Immune Checkpoint Inhibitor-Related Endocrinopathies. <b>2021</b> , 61, 140-146	2
555	[Management of toxicities from immunotherapy]. <b>2021</b> , 146, 1119-1128	0
554	Pembrolizumab Treatment-Induced Liver Toxicity. <b>2021</b> , 15, 742-750	0
553	Immune checkpoint inhibitor-related hepatotoxicity: A review. <b>2021</b> , 27, 5376-5391	10
552	Immune-mediated adverse events in immune checkpoint inhibitors therapy: literature review. <b>2021</b> , 23, 319-326	1



551	Activated osteoarthritis following immune checkpoint inhibitor treatment: an observational study. <b>2021</b> , 9,	1
550	Effect of a multidisciplinary Severe Immunotherapy Complications Service on outcomes for patients receiving immune checkpoint inhibitor therapy for cancer. <b>2021</b> , 9,	1
549	Image intensity histograms as imaging biomarkers: application to immune-related colitis. <b>2021</b> , 7,	1
548	Immune Checkpoint Inhibitors and the Heart. <b>2021</b> , 8, 726426	0
547	Risk of tuberculosis in patients with cancer treated with immune checkpoint inhibitors: a nationwide observational study. <b>2021</b> , 9,	5
546	Drug-induced liver injury: A management position paper from the Latin American Association for Study of the liver. <b>2021</b> , 24, 100321	3
545	Altered interactions between circulating and tissue-resident CD8 T cells with the colonic mucosa define colitis associated with immune checkpoint inhibitors.	0
544	Usage Patterns and Incidence of Thyroid-related Adverse Events in Patients Treated with PD-1 Inhibitors. <b>2021</b> , 31, 188-197	
543	Gastrointestinal Adverse Events Induced by Immune-Checkpoint Inhibitors. <b>2021</b> , 102, 965-973	0
542	Breast cancer treatment-related cardiovascular disturbances: advocacy for a watchful attitude in this never-ending story. <b>2021</b> , 1-13	
541	Real-World Incidence and Management of Immune-Related Adverse Events from Immune Checkpoint Inhibitors: Retrospective Claims-Based Analysis. <b>2021</b> , 39, 789-796	2
540	Management of Immune-Related Adverse Events in Patients With Non-Small Cell Lung Cancer. <b>2021</b> , 11, 720759	1
539	Immune checkpoint inhibitor-related gastritis in a patient with metastatic melanoma. <b>2021</b> , 5, 1218-1219	0
538	Which adjuvant treatment for patients with BRAF-mutant cutaneous melanoma?. <b>2021</b> , 148, 145-155	2
537	Immune-Related Multiple-Organ Injuries Following ICI Treatment With Tislelizumab in an Advanced Non-Small Cell Lung Cancer Patient: A Case Report. <b>2021</b> , 11, 664809	2
536	Embracing cancer immunotherapy with vital micronutrients. <b>2021</b> , 12, 712-724	2
535	Association of Systemic Steroid Treatment and Outcome in Patients Treated with Immune Checkpoint Inhibitors: A Real-World Analysis. <b>2021</b> , 26,	3
534	Simultaneously Combined Cancer Cell- and CTLA4-Targeted NIR-PIT Causes a Synergistic Treatment Effect in Syngeneic Mouse Models. <b>2021</b> , 20, 2262-2273	4

533	Immune checkpoint inhibitors in melanoma. <b>2021</b> , 398, 1002-1014	43
532	Nivolumab-induced membranous nephropathy in a patient with stage IV lung adenocarcinoma. <b>2021</b> , 1	1
531	Critically ill patients with severe immune checkpoint inhibitor related neurotoxicity: A multi-center case series. <b>2021</b> , 65, 126-132	2
530	Cardiovascular adverse events are associated with usage of immune checkpoint inhibitors in real-world clinical data across the United States. <b>2021</b> , 6, 100252	6
529	Neoadjuvant immune checkpoint inhibitors in resectable non-small-cell lung cancer: a systematic review. <b>2021</b> , 6, 100244	9
528	Interstitial Lung Abnormalities: State of the Art. <b>2021</b> , 301, 19-34	7
527	Current treatment of brain tumours. <b>2021</b> , 22, 206-211	0
526	Absence of significant clinical benefit for a systematic routine creatine phosphokinase measurement in asymptomatic patients treated with anti-programmed death protein (ligand) 1 immune checkpoint inhibitor to screen cardiac or neuromuscular immune-related toxicities. <b>2021</b> , 157, 383-390	2
525	Treatment strategy for myocarditis in patients using immune checkpoint inhibitors or combined anti-vascular endothelial growth factor therapy by clinical severity. <b>2021</b> , 157, 10-20	0
524	Toxicity of carbon ion radiotherapy and immune checkpoint inhibitors in advanced melanoma. <b>2021</b> , 164, 1-5	3
523	Interleukin-6 blockade for prophylaxis and management of immune-related adverse events in cancer immunotherapy. <b>2021</b> , 157, 214-224	14
522	Immune checkpoint inhibitors: An emergency medicine focused review. <b>2021</b> , 50, 335-344	2
521	Follow-up Care for Patients Receiving Immune Checkpoint Inhibitors. <b>2021</b> , 8, 596-603	0
520	Continuous monitoring of neutrophils to lymphocytes ratio for estimating the onset, severity, and subsequent prognosis of immune related adverse events. <b>2021</b> , 11, 1324	8
519	Non-IBD and Noninfectious Colitis. <b>2021</b> , 1691-1711	
518	Cutaneous Adverse Events of Immune Checkpoint Inhibitors: A Literature Review. <b>2021</b> , 11, e2021155	12
517	Spectrum and Management of Immune Related Adverse Events Due to Immune Checkpoint Inhibitors. <b>2021</b> , 139-173	
516	Miscellaneous Rheumatic Syndromes. <b>2021</b> , 169-189	

515	The Microbiome and Its Implications in Cancer Immunotherapy. <b>2021</b> , 26,	8
514	Sarcoidosis. <b>2021</b> , 143-167	
513	Non-Rheumatic Immune-Related Adverse Events. <b>2021</b> , 191-253	
512	Ocular adverse events associated with immune checkpoint inhibitors: a novel multidisciplinary management algorithm. <b>2021</b> , 13, 1758835921992989	6
511	Infliximab for the treatment of patients with checkpoint inhibitor-associated acute tubular interstitial nephritis. <b>2021</b> , 10, 1877415	7
510	A multicenter characterization of hepatitis associated with immune checkpoint inhibitors. <b>2021</b> , 10, 1875639	8
509	Checkpoint Inhibitors and Hepatotoxicity. <b>2021</b> , 9,	4
508	Immune checkpoint inhibitor-induced aseptic meningitis and encephalitis: a case-series and narrative review. <b>2021</b> , 12, 20420986211004745	8
507	HLA Class I Antigen Processing Machinery Defects in Cancer Cells-Frequency, Functional Significance, and Clinical Relevance with Special Emphasis on Their Role in T Cell-Based Immunotherapy of Malignant Disease. <b>2020</b> , 2055, 325-350	15
506	Managing Checkpoint Inhibitor Symptoms and Toxicity for Metastatic Melanoma. <b>2020</b> , 1187-1214	2
505	Melanoma. <b>2020</b> , 225-246	1
504	Treatment Strategies in Head and Neck Cancers. <b>2020</b> , 273-294	1
503	Gastrointestinal Tract Adverse Events. <b>2020</b> , 1244, 247-253	2
502	Immune-Related Adverse Events: Pneumonitis. <b>2020</b> , 1244, 255-269	12
501	Immune Checkpoint Inhibitors (ICIs)-Related Cardiotoxicity. <b>2020</b> , 1244, 277-285	5
500	SEOM clinical guideline for the management of immune-related adverse events in patients treated with immune checkpoint inhibitors (2019). <b>2020</b> , 22, 213-222	7
499	Immune checkpoint inhibitors: a narrative review of considerations for the anaesthesiologist. <b>2020</b> , 124, 251-260	18
498	Real-life experience with nivolumab monotherapy in patients with advanced lung cancer: Efficacy and immune-related adverse events at Jiangsu Cancer Hospital, Nanjing, China. <b>2020</b> , 10, 93-99	0

497	Metabolic consequences of immune checkpoint inhibitors: A new challenge in clinical practice. <b>2020</b> , 151, 102979	3
496	Toxicities from immunotherapy: From clinical trials to real-world clinical practice. <b>2020</b> , 155, 541-547	0
495	Checkpoint inhibitor immunotherapy in kidney cancer. <b>2020</b> , 17, 137-150	81
494	Anti-programmed cell death-1 and anti-programmed cell death ligand-1 immune-related liver diseases: from clinical pivotal studies to real-life experience. <b>2020</b> , 20, 1047-1059	3
493	Durvalumab for the treatment of PD-L1 non-small cell lung cancer. <b>2021</b> , 6, 95-105	1
492	Bilateral Corneal Perforation in a Patient Under Anti-PD1 Therapy. <b>2021</b> , 40, 245-247	2
491	ACE2 and TMPRSS2 expression by clinical, HLA, immune, and microbial correlates across 34 human cancers and matched normal tissues: implications for SARS-COV-2 COVID-19.	1
490	Predictive and sensitive biomarkers for thyroid dysfunctions during treatment with immune-checkpoint inhibitors. <b>2020</b> , 111, 1468-1477	35
489	Atezolizumab-induced myositis and myocarditis in a patient with metastatic urothelial carcinoma. <b>2020</b> , 13,	6
488	Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of lymphoma. <b>2020</b> , 8,	3
487	Guidelines for the Diagnosis and Treatment of Hepatocellular Carcinoma (2019 Edition). <b>2020</b> , 9, 682-720	108
486	Acute Bilateral Uveitis, Hypotony, and Cataracts Associated with Ipilimumab and Nivolumab Therapy: Optical Coherence Tomography Angiography Findings. <b>2020</b> , 11, 606-611	2
485	The alveolar immune cell landscape is dysregulated in checkpoint inhibitor pneumonitis. <b>2019</b> , 129, 4305-4315	47
484	Time to dissect the autoimmune etiology of cancer antibody immunotherapy. <b>2020</b> , 130, 51-61	34
483	Immune-related adverse events: a retrospective look into the future of oncology in the intensive care unit. <b>2020</b> , 10, 143	8
482	Toxicity Management of Front-Line Pembrolizumab Combined With Axitinib in Clear Cell Metastatic Renal Cell Carcinoma: A Case Study Approach. <b>2020</b> , 16, 15s-19s	3
481	Anticancer Drugs and the Nervous System. <b>2020</b> , 26, 732-764	6
480	Neurotoxicity of Cancer Therapies. <b>2020</b> , 26, 1646-1672	4

479	Immune checkpoint inhibitor-induced colitis: A comprehensive review. <b>2019</b> , 7, 405-418	96
478	Gastrointestinal Adverse Effects of Immunotherapeutic Agents: A Systematic Review. <b>2020</b> , 13, 227-232	2
477	Management of endocrine immune-related adverse events of immune checkpoint inhibitors: an updated review. <b>2020</b> , 9, R207-R228	24
476	Anticancer Drug-induced Thyroid Dysfunction. <b>2020</b> , 16, 32-39	7
475	An Update on Immune Checkpoint Inhibitor-related Hypophysitis. <b>2020</b> , 16, 117	2
474	Bronchopleural fistula following a video-assisted thoracoscopic surgery lobectomy after neoadjuvant therapy of pembrolizumab: a case report and literature review. <b>2020</b> , 8, 1691	1
473	Drug-Induced liver Injury Associated with Severe Cutaneous Hypersensitivity Reactions: A Complex Entity in Need of a Multidisciplinary Approach. <b>2019</b> , 25, 3855-3871	8
472	Immune Checkpoint Inhibitors-related Rheumatic Diseases: What Rheumatologist Should Know?. <b>2019</b> , 15, 201-208	8
471	Follow-Up of Cancer Patients Receiving Anti-PD-(L)1 Therapy Using an Electronic Patient-Reported Outcomes Tool (KISS): Prospective Feasibility Cohort Study. <b>2020</b> , 4, e17898	7
470	Endocrine adverse events related with immune checkpoint inhibitors: an update for clinicians. <b>2020</b> , 12, 481-510	3
469	New medical approaches in advanced ovarian cancer. <b>2019</b> , 110, 367-384	3
468	Immune Response Checkpoint Inhibitors: New Risks of a New Class of Antitumor Agents. <b>2020</b> , 8, 9-22	4
467	Biomarkers for precision immunotherapy in the metastatic setting: hope or reality?. <b>2020</b> , 14, 1150	9
466	Case Report: A Case of Pituitary Carcinoma Treated With Sequential Dual Immunotherapy and Vascular Endothelial Growth Factor Inhibition Therapy. <b>2020</b> , 11, 576027	6
465	Progress and Challenges in Precise Treatment of Tumors With PD-1/PD-L1 Blockade. <b>2020</b> , 11, 339	36
464	Emergency Department Utilization for Patients Receiving Immune Checkpoint Inhibitors: A Retrospective Analysis of Identification and Outcomes for Those Presenting for Immune-Related Adverse Events. <b>2020</b> , 28, 52-59	1
463	Autoimmune and non-autoimmune related complications of successful lung cancer treatment with pembrolizumab. <b>2020</b> , 14, 122-126	1
462	Inclusion of Anesthesiologists and Surgeons While Developing Guidelines for Management of Immune-Related Adverse Events. <b>2020</b> , 3, 56-57	1

461	Programmed cell death-1 inhibitor-related sclerosing cholangitis: A systematic review. <b>2020</b> , 26, 353-365	23
460	[Chinese Experts Consensus on Immune Checkpoint Inhibitors for Non-small Cell Lung Cancer (2019 version)]. <b>2020</b> , 23, 65-76	8
459	Elevated levels of IL-17A and IL-35 in plasma and bronchoalveolar lavage fluid are associated with checkpoint inhibitor pneumonitis in patients with non-small cell lung cancer. <b>2020</b> , 20, 611-622	10
458	Rheumatic complications in cancer patients treated with immune checkpoint inhibitors. <b>2019</b> , 34, 1197-1209	6
457	Adverse Events of Oncologic Immunotherapy and Their Management. <b>2019</b> , 6, 212-226	7
456	Adverse effects of immuno-oncology drugs-Awareness, diagnosis, and management: A literature review of immune-mediated adverse events. <b>2019</b> , 56, S10-S22	3
455	Cardiotoxicity of FDA-approved immune checkpoint inhibitors: A rare but serious adverse event. <b>2018</b> , 1, 68-77	8
454	Cardiac adverse events of immune checkpoint inhibitors in oncology patients: A systematic review and meta-analysis. <b>2020</b> , 12, 584-598	6
453	Vedolizumab in combined immune checkpoint therapy-induced infliximab-refractory colitis in a patient with metastatic melanoma: A case report. <b>2019</b> , 10, 350-357	3
452	Management of Immunotherapy-Related Toxicities, Version 1.2019. <b>2019</b> , 17, 255-289	246
451	Preexisting Autoimmune Disease: Implications for Immune Checkpoint Inhibitor Therapy in Solid Tumors. <b>2019</b> , 17, 750-757	52
450	Glucocorticoid use and complications following immune checkpoint inhibitor use in melanoma. <b>2020</b> , 20, 163-168	13
449	Therapeutic and Systemic Adverse Events of Immune Checkpoint Inhibitors Targeting the PD-1/PD-L1 axis for Clinical Management of NSCLC. <b>2021</b> , 30, 9636897211041587	3
448	The Advancement in Diagnosis and Therapy of Liver Injury Induced by Immune Checkpoint Inhibitors. <b>2021</b> , 11, 4628-4634	
447	Clinical Characteristics and Outcomes of Oral Mucositis Associated With Immune Checkpoint Inhibitors in Patients With Cancer. <b>2021</b> ,	2
446	Questions pratiques en immunothérapie dans le cancer bronchique non ^petites cellules : dose, durée, rythme de traitement, r̄introduction. <b>2021</b> , 13, 2S164-2S173	
445	Gestion des toxicit̄s de l̄immunoth̄rapie: Management of immunotherapy toxicities. <b>2021</b> , 13, 2S258-2S265	
444	Rheumatological Immune-related Adverse Events of Checkpoints Inhibitors: a Narrative Review for the Latin American Rheumatologist. <b>2021</b> ,	0

443	Immuno-oncologic care during COVID-19: Challenges and opportunities for improving clinical care and investigation.. <b>2021</b> , 2, 75-82	
442	Dramatic, significant metabolic response to a one-time pembrolizumab treatment following a relapse of pre-existing organizing pneumonia in a patient with advanced non-small cell lung cancer: A case report. <b>2021</b> , 12, 3076-3079	2
441	Cardiac Toxicity Associated with Immune Checkpoint Inhibitors: A Systematic Review. <b>2021</b> , 13,	6
440	The Importance of Primary Care in Cardio-Oncology. <b>2021</b> , 22, 107	
439	Immune Checkpoint Inhibitors and Kidney Toxicity: Advances in Diagnosis and Management.. <b>2021</b> , 3, 1074-1081	3
438	Risk of Pneumonitis Associated With Immune Checkpoint Inhibitors in Melanoma: A Systematic Review and Network Meta-Analysis. <b>2021</b> , 11, 651553	0
437	Hallmarks of response, resistance, and toxicity to immune checkpoint blockade. <b>2021</b> , 184, 5309-5337	70
436	Imaging of Cancer Immunotherapy: Response Assessment Methods, Atypical Response Patterns, and Immune-Related Adverse Events, From the Special Series on Imaging of Inflammation. <b>2021</b> ,	1
435	Insights into Potential Pathogenesis and Treatment Options for Immune-Checkpoint Inhibitor-Related Pneumonitis. <b>2021</b> , 9,	1
434	Grade 4 Neutropenia Secondary to Immune Checkpoint Inhibition - A Descriptive Observational Retrospective Multicenter Analysis. <b>2021</b> , 11, 765608	1
433	The Continuum of Thyroid Disorders Related to Immune Checkpoint Inhibitors: Still Many Pending Queries. <b>2021</b> , 13,	1
432	Conditional PD-1/PD-L1 Probody Therapeutics Induce Comparable Antitumor Immunity but Reduced Systemic Toxicity Compared with Traditional Anti-PD-1/PD-L1 Agents. <b>2021</b> , 9, 1451-1464	0
431	Rare case of chemotherapy-refractory metastatic vaginal squamous cell carcinoma with complete response to concurrent pembrolizumab and radiotherapy- case report and literature review.. <b>2021</b> , 38, 100878	0
430	Uncommon inflammatory/immune-related myelopathies. <b>2021</b> , 361, 577750	0
429	Pericardial Effusion with Tamponade, an Immune-Related Adverse Event Associated with Nivolumab Therapy: A Case Report and Review of the Literature. <b>2018</b> , 09, 1039-1047	
428	Integration of Next-generation Sequencing and Immune Checkpoint Inhibitors in Targeted Symptom Control and Palliative Care in Solid Tumor Malignancies: A Multidisciplinary Clinician Perspective. <b>2018</b> , 10, e2909	2
427	Evolving Role of the Oncology Nurse in the Care of Patients with Melanoma. <b>2019</b> , 1-27	1
426	Consequences of genitourinary malignancies therapy on cardiovascular system. <b>2018</b> , 19, 228-232	

- 425 Managing Checkpoint Inhibitor Symptoms and Toxicity. **2019**, 1-28
- 424 Prophylaxe und Therapie von Komplikationen der systemischen Tumorthherapie. **2019**, 1-18
- 423 Introduction to Melanoma Immunology. **2019**, 1-15
- 422 Melanoma Immunology and Immunotherapy. **2019**, 1-15
- 421 Oncology in the Primary Care. **2019**, 413-425
- 420 Checkpoint Inhibitor Immunotherapy for Head and Neck Cancer: Incorporating Care Step Pathways for Effective Side-Effect Management. **2019**, 10, 37-46 5
- 419 PD-1/PD-L1 Inhibitors for Non-Small Cell Lung Cancer: Incorporating Care Step Pathways for Effective Side-Effect Management. **2019**, 10, 21-35 7
- 418 Immune-Related Adverse Events From Immunotherapy: Incorporating Care Step Pathways to Improve Management Across Tumor Types. **2019**, 10, 47-62 7
- 417 Metastasis suppression and enhancement of anti-tumour immunity by targeting the FSTL1-DIP2A axis. **2019**, 8, S149-S151
- 416 Vedolizumab Achieved Clinical and Histologic Remission in a Patient with Lung Cancer Who Had a Steroid-Refractory Upper Gastrointestinal Injury Due to Nivolumab Treatment. **2019**, 2, 40-45 5
- 415 The Advanced Practice Provider Perspective: Treating Patients With Immuno-Oncology Combination Therapy Across Tumor Types. **2019**, 10, 367-386
- 414 Dysprosium metallicum, un médicament homéopathique pour la prévention des effets secondaires de l'immunothérapie. **2019**, 10, 101-106
- 413 Vedolizumab in combined immune checkpoint therapy-induced infliximab-refractory colitis in a patient with metastatic melanoma: A case report. **2019**, 10, 349-356
- 412 Immunotherapy, Cancer and Rheumatic Diseases. **2019**, 15, 249-251 0
- 411 Budosened Treatment of Avelumab Induced Autoimmune Colitis in Patient With Metastatic Merkel Cell Carcinoma; A Case Report. **2019**, 1-4
- 410 Kanser immünoterapisi sırasında gelişen inflamatuvar artrit olgusu. 64-66
- 409 GI Toxicities from Cancer Therapy. **2020**, 1-39
- 408 Paradigms in Cancer Drug Development: A Universe with Many Galaxies. **2020**, 17-44



407	Onkologika. <b>2020</b> , 671-732	1
406	Gastrointestinal Toxicities of Immunotherapy. <b>2020</b> , 201-222	
405	Cardivascular Toxicities of Immunotherapy. <b>2020</b> , 259-276	
404	Endocrine Toxicities of Immunotherapy. <b>2020</b> , 187-200	
403	Management of Acute Pancreatitis Associated With Checkpoint Inhibitors. <b>2020</b> , 11, 49-62	1
402	A Case of Acute Heart Failure Following Immunotherapy for Metastatic Lung Cancer. <b>2020</b> , 12, e8093	3
401	Cardiac Adverse Events of Immune Checkpoint Inhibitors in Oncology Patients: A Systematic Review and Meta-Analysis.	
400	Side effects and management in immunotherapy based on immune checkpoint inhibitors. <b>2020</b> , 28, 755-764	0
399	Uveitis associated with cancer immunotherapy: long-term outcomes. <b>2021</b> , 13, 1465-1481	0
398	Immune checkpoint inhibition for the treatment of cancers: An update and critical review of ongoing clinical trials. <b>2021</b> , 232, 108873	1
397	Immunotherapy for Stage III NSCLC: Durvalumab and Beyond. <b>2021</b> , 12, 123-131	1
396	Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: ASCO Guideline Update. <b>2021</b> , JCO2101440	55
395	Hepatobiliary Adverse Events. <b>2020</b> , 1244, 271-276	2
394	The Mechanism and Management of Adverse Cardiac Reactions Induced by Immune Checkpoint Inhibitors Therapy. <b>2020</b> , 2020, 8367651	
393	Manejo de las toxicidades inmunomediadas en los pacientes con melanoma. <b>2020</b> , 35, 649-660	
392	Current immunotherapy in gastrointestinal malignancies A Review. <b>2021</b> , 69, 689-696	2
391	Pulmonary Toxicities of Immunotherapy. <b>2020</b> , 243-252	
390	Rheumatological Toxicities of Immunotherapy. <b>2020</b> , 277-286	

- 389 Immunotherapeutic approaches in HNSCC. **2020**, 117-142 0
- 388 Axitinib plus Immuncheckpoint-Inhibitor: evidenz- und expertenbasierte Konsensusempfehlungen für die Behandlungsoptimierung und das Management von therapieassoziierten Nebenwirkungen. **2020**, 7, 180-189
- 387 Follow-Up of Cancer Patients Receiving Anti-PD-(L)1 Therapy Using an Electronic Patient-Reported Outcomes Tool (KISS): Prospective Feasibility Cohort Study (Preprint).
- 386 Development of a Functional Assessment of Chronic Illness Therapy item library and primary symptom list for the assessment of patient-reported adverse events associated with immune checkpoint modulators. **2020**, 6, 2
- 385 [New therapies for skin cancers]. **2020**, 147, 255-257
- 384 Rheumatic Manifestations and Diseases From Immune Checkpoint Inhibitors in Cancer Immunotherapy. **2021**, 8, 762247 3
- 383 New Insights into the Role of PD-1 and Its Ligands in Allergic Disease. **2021**, 22, 2
- 382 Molecular Pathology of Lung Cancer. **2021**, 1
- 381 Durable response after immunotherapy discontinuation for delayed and severe immune-related adverse events: a case report. **2021**, 13, 1379-1386 0
- 380 Immunotherapy for Metastatic Urothelial Cancer. **2021**, 201-213
- 379 [Endocrine side effects of cancer immunotherapy]. **2020**, 145, 1736-1741
- 378 Immune-related Pulmonary Toxicity From Cancer Immunotherapy: A Systematic Approach. **2020**, 27, 183-192
- 377 Relationship between cardiac arrhythmias and anticancer therapy. **2020**, 19, 2417 1
- 376 Role of Infliximab in Immune Checkpoint Inhibitor-Induced Pneumonitis. **2020**, 3, 172-174 3
- 375 Winning the Fight Against Cancer. **2020**, 49, 779-788 1
- 374 Immunotherapy induced enterocolitis and gastritis - What to do and when?. **2020**, 48-49, 101703 3
- 373 [Diagnosis and Treatment Recommendation and Exploration for Critical and Refractory Adverse Effects Related to Immunocheckpoint Inhibitors]. **2019**, 22, 605-614
- 372 Modeling multi-needle injection into solid tumor. **2019**, 9, 2209-2215

371	[Progress of Steroids Effect on Efficacy of Immune Checkpoint Inhibitors]. <b>2019</b> , 22, 786-793	
370	Extracorporeal Photochemotherapy: Mechanistic Insights Driving Recent Advances and Future Directions. <b>2020</b> , 93, 145-159	2
369	[Progress in Neoadjuvant Immunotherapies for Resectable Non-small Cell Lung Cancer]. <b>2020</b> , 23, 371-380	
368	Retinopathy of prematurity and neonatal gut microbiome: An interview with Professor Dimitra Skondra, Associate Professor of Ophthalmology and Vitreoretinal Surgeon at The University of Chicago (USA). <b>2020</b> , 20, 294	1
367	[Chinese Experts Consensus on Immune Checkpoint Inhibitors ?for Non-small Cell Lung Cancer (2020 Version)]. <b>2021</b> , 24, 217-235	1
366	Gastrointestinal and liver adverse effects of anti-tumoral immune therapy: from recognition to treatment. <b>2021</b> , 14, 195-199	
365	Neoadjuvant immunotherapy for resectable non-small cell lung cancer. <b>2021</b> , 11, 2521-2536	2
364	Diagnosis and Management of Immune Checkpoint Inhibitor Colitis. <b>2021</b> , 17, 358-366	0
363	Treatment-free Survival after Immune Checkpoint Inhibitor Therapy versus Targeted Therapy for Advanced Renal Cell Carcinoma: 42-Month Results of the CheckMate 214 Trial. <b>2021</b> ,	4
362	Pembrolizumab-Induced Type 1 Diabetes in a 95-Year-Old Veteran With Metastatic Melanoma.. <b>2021</b> , 38, 520-523	
361	Immune Checkpoint Blockade and Skin Toxicity Pathogenesis. <b>2021</b> ,	0
360	Dermatologic Events Associated with the Anti-CCR4 Antibody Mogamulizumab: Characterization and Management. <b>2021</b> , 1	1
359	Adverse Effects and Toxicity of Immune Checkpoint Inhibitors For Patients With Urothelial Carcinoma. <b>2021</b> , 12, 710943	1
358	Immune Checkpoint Inhibitor Therapy Induces Inflammatory Activity in the Large Arteries of Lymphoma Patients under 50 Years of Age. <b>2021</b> , 10,	
357	Systematic review: disease activity indices for immune checkpoint inhibitor-associated enterocolitis. <b>2021</b> ,	0
356	Increased risk of thyroid dysfunction by PD-1 and CTLA-4 blockade in patients without thyroid autoantibodies at baseline. <b>2021</b> ,	4
355	Refractory Immune Checkpoint Inhibitor-induced Colitis Improved by Fecal Microbiota Transplantation: A Case Report. <b>2021</b> ,	4
354	Checkpoint Inhibition in Bladder Cancer: Clinical Expectations, Current Evidence, and Proposal of Future Strategies Based on a Tumor-Specific Immunobiological Approach. <b>2021</b> , 13,	3

353	Patterns and outcomes of immune-related adverse events in solid tumor patients treated with immune checkpoint inhibitors in Thailand: a multicenter analysis. <b>2021</b> , 21, 1275	0
352	Evaluation and clinical impact of a pharmacist-led, interdisciplinary service focusing on education, monitoring and toxicity management of immune checkpoint inhibitors. <b>2021</b> , 10781552211061133	0
351	Immunotherapies for hepatocellular carcinoma. <b>2021</b> ,	57
350	Body mass index is not associated with survival outcomes and immune-related adverse events in patients with Hodgkin lymphoma treated with the immune checkpoint inhibitor nivolumab. <b>2021</b> , 19, 489	0
349	A Network Comparison on Safety Profiling of Immune Checkpoint Inhibitors in Advanced Lung Cancer.. <b>2021</b> , 12, 760737	0
348	Hepatocellular carcinoma with complete response to the immunotherapy: the oncologist's dilemma.. <b>2022</b> , 11, 119-122	
347	Immune Checkpoint Inhibitor (ICI)-Related Cardiotoxicity.. <b>2021</b> , 1342, 377-387	
346	Colitis Induced by Immune-checkpoint Inhibitors. <b>2021</b> , 74, 599-605	
345	Success is not final, failure is not fatal: The changing landscape of systemic therapy for advanced hepatocellular carcinoma. <b>2021</b> , 8, 127	
344	Hepatobiliary and Pancreatic Adverse Events.. <b>2021</b> , 1342, 339-355	0
343	Pulmonary Toxicities of Immunotherapy.. <b>2021</b> , 1342, 357-375	
342	Immunotherapy-Mediated Luminal Gastrointestinal Toxicities.. <b>2021</b> , 1342, 331-337	
341	C-reactive protein flare-response predicts long-term efficacy to first-line anti-PD-1-based combination therapy in metastatic renal cell carcinoma.. <b>2021</b> , 10, e1358	1
340	Immunotherapy toxicity: identification and management.. <b>2022</b> , 1	2
339	Bridging the Gap: Connecting the Mechanisms of Immune-Related Adverse Events and Autoimmunity Through PD-1.. <b>2021</b> , 9, 790386	1
338	The importance of immune checkpoints in immune monitoring: A future paradigm shift in the treatment of cancer.. <b>2021</b> , 146, 112516	7
337	[Opinion] Retinopathy of prematurity and neonatal gut microbiome: An interview with Professor Dimitra Skondra, Associate Professor of Ophthalmology and Vitreoretinal Surgeon at The University of Chicago (USA). <b>2020</b> , 20, 1-1	1
336	Case Series of Steroid-Resistant Immune Checkpoint Inhibitor Associated Myocarditis: A Comparative Analysis of Corticosteroid and Tofacitinib Treatment.. <b>2021</b> , 12, 770631	2

- 335 Eosinophils and Melanoma: Implications for Immunotherapy.. **2021**, 1
- 334 [What should specialist in internal medicine be aware of in patients treated with biologics? : Infections and autoimmune phenomena].. **2022**, 63, 165
- 333 Paraneoplastic Autoimmune Neurological Syndromes and the Role of Immune Checkpoint Inhibitors.. **2022**, 1 0
- 332 Multiple rechallenges with anti-PD-1 immunotherapy in patients with checkpoint inhibitor-related pneumonitis: A report of two cases.. **2022**, 10781552211073962
- 331 Harnessing big data to characterize immune-related adverse events.. **2022**, 1
- 330 CD19 CAR-T Cell Therapy Induced Immunotherapy Associated Interstitial Pneumonitis: A Case Report.. **2022**, 13, 778192 1
- 329 Adverse Events of Immune Checkpoint Inhibitors Therapy for Urologic Cancer Patients in Clinical Trials: A Collaborative Systematic Review and Meta-analysis.. **2022**, 2
- 328 Cytokine Release Syndrome in Cancer Patients Receiving Immune Checkpoint Inhibitors: A Case Series of 25 Patients and Review of the Literature.. **2022**, 13, 807050 3
- 327 Defining unique clinical hallmarks for immune checkpoint inhibitor-based therapies.. **2022**, 10, 2
- 326 CNS and PNS manifestation in immune checkpoint inhibitors: A systematic review.. **2021**, 432, 120089 0
- 325 Safety of Immune Checkpoint Inhibitors in the Peri-operative Setting. **2022**, 231-244
- 324 Immunotherapy and Gene Therapy: New Challenges in the Diagnosis and Management of Drug-Induced Liver Injury.. **2021**, 12, 786174 0
- 323 A Review of Potential Role of Capsule Endoscopy in the Work-Up for Chemotherapy-Induced Diarrhea.. **2022**, 10, 0
- 322 Pembrolizumab-Related Side Effects: Acute Renal Failure and Severe Neurological Toxicity.. **2022**, 58, 1
- 321 The current landscape of immunotherapy for pediatric brain tumors.. **2022**, 3, 11-24 1
- 320 Association of Cutaneous Immune-Related Adverse Events With Increased Survival in Patients Treated With Anti-Programmed Cell Death 1 and Anti-Programmed Cell Death Ligand 1 Therapy.. **2022**, 6
- 319 Retrospective study evaluating immune-related adverse events in cancer patients treated with pembrolizumab.. **2022**, 10781552221074374
- 318 Audiovestibular Toxicity Secondary to Immunotherapy: Case Series and Literature Review. **2022**, 5, 2-6

317	Biomarkers and risk factors for the early prediction of immune-related adverse events: a review.. <b>2022</b> , 1-12	1
316	Bilateral diffuse uveal melanocytic proliferation: Report of a novel optical coherence tomography finding and clinical response to plasmapheresis.. <b>2022</b> , 25, 101349	1
315	Role of Corticosteroids in Drug-Induced Liver Injury. A Systematic Review.. <b>2022</b> , 13, 820724	1
314	A Guide to Implementing Immune Checkpoint Inhibitors within a Cancer Program: Experience from a Large Canadian Community Centre.. <b>2022</b> , 29, 869-880	0
313	Harnessing the Therapeutic Potential of Extracellular Vesicles for Biomedical Applications Using Multifunctional Magnetic Nanomaterials.. <b>2022</b> , e2104783	5
312	Real-World Experience with Nivolumab in Metastatic Renal Cell Carcinoma Patients Who Have Progressed on Prior Therapies: A Single-Center Study from India.	
311	Managing Metastatic Melanoma in 2022: A Clinical Review.. <b>2022</b> , OP2100686	8
310	A Case Report of Non-Bacterial Cystitis Caused by Immune Checkpoint Inhibitors.. <b>2021</b> , 12, 788629	1
309	Immune Checkpoint Inhibitor-Associated Colitis: From Mechanism to Management.. <b>2021</b> , 12, 800879	2
308	Nursing care of a patient with programmed cell death protein-1 immunotherapy-related myocarditis combined with coronary heart disease. <b>2021</b> , 3, 93	
307	Strategies to mitigate the toxicity of cancer therapeutics. <b>2022</b> ,	0
306	Neurologic complications of immune modulatory therapy. <b>2022</b> , 537-551	
305	Retrospective analysis of immune-related adverse events of the immune checkpoint inhibitors of PD-1/PD-l1 in the Fujian provincial hospital. <b>2022</b> , 20, 1721727X2210915	1
304	Neurological complications of lung cancer. <b>2022</b> , 243-276	
303	Development of management strategies for immune-related adverse effects of immunotherapies used in oncological treatment.. <b>2022</b> , 9, 7-11	
302	Neurologic Toxicity of Immune Checkpoint Inhibitors: A Review of Literature.. <b>2022</b> , 13, 774170	0
301	Neurotoxicity and safety of the rechallenge of immune checkpoint inhibitors: a growing issue in neuro-oncology practice.. <b>2022</b> , 43, 2339	1
300	Immune Reconstitution Inflammatory Syndrome Associated Kaposi Sarcoma.. <b>2022</b> , 14,	1

299	Case 6-2022: A 68-Year-Old Man with Fatigue, Weight Loss, and Hyperglycemia.. <b>2022</b> , 386, 781-787	1
298	Impact of Glucocorticoid Use in Oncology in the Immunotherapy Era.. <b>2022</b> , 11,	3
297	Risk factors for immune checkpoint inhibitor-related pneumonitis in non-small cell lung cancer.. <b>2022</b> , 11, 295-306	0
296	Immunotherapy Associated Neurotoxicity in Pediatric Oncology.. <b>2022</b> , 12, 836452	0
295	Patient and treatment characteristics of emergency presentations due to immune-mediated toxicities.. <b>2022</b> , 164, 62-69	0
294	Review of Immune-Related Adverse Events (irAEs) in Non-Small-Cell Lung Cancer (NSCLC)-Their Incidence, Management, Multiorgan irAEs, and Rechallenge.. <b>2022</b> , 10,	1
293	Incidence, predictors and 6-month overall outcome of acute kidney injury in Chinese patients receiving PD-1 inhibitors.. <b>2022</b> ,	1
292	Hemorrhagic Chemosi s Associated With Isatuximab Use in an Elderly Lady With Multiple Myeloma.. <b>2022</b> , 14, e22764	
291	Breaking the Child-Pugh Dogma in Hepatocellular Carcinoma.. <b>2022</b> , JCO2102373	1
290	Holistic Approach to Immune Checkpoint Inhibitor-Related Adverse Events.. <b>2022</b> , 13, 804597	4
289	From Photon Beam to Accelerated Particle Beam: Antimetastasis Effect of Combining Radiotherapy With Immunotherapy.. <b>2022</b> , 10, 847119	0
288	Predictive Markers for Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer.. <b>2022</b> , 11,	1
287	Validation of an online application to identify potential immune-related adverse events associated with immune checkpoint inhibitors based on the patient's symptoms.. <b>2022</b> , 17, e0265230	
286	Rate and risk factors of recurrent immune checkpoint inhibitor-related pneumonitis in patients with lung cancer.. <b>2022</b> , 11, 381-392	0
285	Health-related quality of life in cancer immunotherapy: a systematic perspective, using causal loop diagrams.. <b>2022</b> , 1	0
284	Thalidomide for prevention of camrelizumab-induced reactive cutaneous capillary endothelial proliferation.. <b>2022</b> ,	0
283	Advances in Knowledge and Management of Immune-Related Adverse Events in Cancer Immunotherapy.. <b>2022</b> , 13, 779915	0
282	Checkpoint Inhibitors and Induction of Celiac Disease-like Condition.. <b>2022</b> , 10,	0

281	PD-1/PD-L1 Inhibitors in Patients With Preexisting Autoimmune Diseases.. <b>2022</b> , 13, 854967	2
280	Efficiency of Electronic Health Record Assessment of Patient-Reported Outcomes After Cancer Immunotherapy: A Randomized Clinical Trial.. <b>2022</b> , 5, e224427	2
279	Multidisciplinary clinical guidance on trastuzumab deruxtecan (T-DXd)-related interstitial lung disease/pneumonitis-Focus on proactive monitoring, diagnosis, and management.. <b>2022</b> , 106, 102378	4
278	Association Between Clinical Factors and Result of Immune Checkpoint Inhibitor Related Myasthenia Gravis: A Single Center Experience and Systematic Review.. <b>2022</b> , 13, 858628	0
277	Cardiac Magnetic Resonance Imaging in Immune Check-Point Inhibitor Myocarditis: A Systematic Review.. <b>2022</b> , 8,	0
276	Checkpoint Inhibitor Pneumonitis Induced by Anti-PD-1/PD-L1 Therapy in Non-Small-Cell Lung Cancer: Occurrence and Mechanism.. <b>2022</b> , 13, 830631	3
275	Predictive value of immune-related adverse events during pembrolizumab treatment in non-small cell lung cancer.. <b>2022</b> ,	
274	Current options of non-surgical treatment of melanoma in practice. <b>2021</b> , 15, 78-82	
273	The management of toxicities from immune, targeted and ADCs treatments in patients with urothelial cancer.. <b>2021</b> ,	0
272	Immunotherapy in Patients with Advanced Non-Small Cell Lung Cancer Lacking Driver Mutations and Future Perspectives.. <b>2021</b> , 14,	2
271	European recommendations for management of immune checkpoint inhibitors-derived dermatologic adverse events. The EADV task force 'Dermatology for cancer patients' position statement.. <b>2021</b> ,	9
270	Analysis of immune-mediated reactions in patients with non-small cell lung cancer treated with nivolumab and its association with effectiveness.. <b>2021</b> , 10781552211067429	0
269	Case Report: Glucocorticoid Effect Observation in a Ureteral Urothelial Cancer Patient With ICI-Associated Myocarditis and Multiple Organ Injuries.. <b>2021</b> , 12, 799077	1
268	CANDIED: A Pan-Canadian Cohort of Immune Checkpoint Inhibitor-Induced Insulin-Dependent Diabetes Mellitus.. <b>2021</b> , 14,	1
267	Immune Checkpoint Inhibition in Non-Melanoma Skin Cancer: A Review of Current Evidence.. <b>2021</b> , 11, 734354	1
266	Differential diagnosis and management of immune checkpoint inhibitor-induced colitis: A comprehensive review. <b>2021</b> , 11, 79-92	0
265	Nivolumab-induced liver injury with a steroid-refractory increase in biliary enzymes, in a patient with malignant mesothelioma: An autopsy case report.. <b>2021</b> , 9, e05174	0
264	Immune checkpoint inhibitor-related adverse events in lung cancer: Real-world incidence and management practices of 1905 patients in China.. <b>2021</b> ,	4



263	PD-1/PD-L1 Inhibitor-Associated Myocarditis: Epidemiology, Characteristics, Diagnosis, Treatment, and Potential Mechanism.. <b>2022</b> , 13, 835510	1
262	Distinct molecular and immune hallmarks of inflammatory arthritis induced by immune checkpoint inhibitors for cancer therapy.. <b>2022</b> , 13, 1970	2
261	Immune Checkpoint Inhibitors as Therapy to Down-Stage Hepatocellular Carcinoma Prior to Liver Transplantation.. <b>2022</b> , 14,	2
260	The impact of an immuno-oncology service at a regional cancer centre based in the north west of the UK.. <b>2022</b> , 31, 414-420	
259	Association of Immune Checkpoint Inhibitors With Neurologic Adverse Events: A Systematic Review and Meta-analysis.. <b>2022</b> , 5, e227722	1
258	Immune-Related Adverse Events (irAEs) in Cancer, with Inputs from a Nursing Expert: A Review. 43,	
257	Immune checkpoint inhibitor-related thyroid dysfunction.. <b>2022</b> , 101660	0
256	DataSheet_1.csv. <b>2020</b> ,	
255	Image_1.tif. <b>2020</b> ,	
254	Image_2.tif. <b>2020</b> ,	
253	Image_3.tif. <b>2020</b> ,	
252	Image_4.tif. <b>2020</b> ,	
251	Image_5.tif. <b>2020</b> ,	
250	Image_6.tif. <b>2020</b> ,	
249	Image_7.tif. <b>2020</b> ,	
248	Image_8.tif. <b>2020</b> ,	
247	Image_9.tif. <b>2020</b> ,	
246	Image_1.jpeg. <b>2020</b> ,	

245 Image\_2.jpeg. **2020**,

244 Image\_3.jpeg. **2020**,

243 Image\_4.jpeg. **2020**,

242 Table\_1.DOCX. **2020**,

241 Table\_1.docx. **2019**,

240 Image\_1.TIF. **2020**,

239 Image\_2.TIF. **2020**,

238 Image\_3.TIF. **2020**,

237 Image\_4.TIF. **2020**,

236 Image\_5.TIF. **2020**,

235 Image\_6.TIF. **2020**,

234 Table\_1.DOCX. **2020**,

233 Table\_2.DOCX. **2020**,

232 DataSheet\_1.docx. **2020**,

231 Paraneoplastic neurological syndrome: growing spectrum and relevance.. **2022**, 1

○

230 Immunotherapy-induced Colitis: A Comprehensive Review of Epidemiology, Clinical Presentation, Diagnostic Workup, and Management Plan.. **2022**,

○

229 An Unusual Case of Pericarditis. **2021**, 37, 648-651

228 Autoimmune Polyendocrinopathy Induced by an Antibody (KN046) That Simultaneously Inhibits PD-L1 and CTLA-4: A Case Report and Literature Review.. **2022**, 15, 1253-1260

1

227	Gastrointestinal Toxicities of Immune Checkpoint Inhibitors Are Associated With Enhanced Tumor Responsiveness and Improved Survival.. <b>2022</b> , 15, 56-66	0
226	AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGY (AACE) DISEASE STATE CLINICAL REVIEW EVALUATION AND MANAGEMENT OF IMMUNE CHECKPOINT INHIBITOR-MEDIATED ENDOCRINOPATHIES: A PRACTICAL CASE-BASED CLINICAL APPROACH.. <b>2022</b> ,	0
225	Hemophagocytic Lymphohistiocytosis Secondary to Immune Checkpoint Inhibitor Therapy.. <b>2022</b> , 13, 49-52	1
224	Clinical Combinatorial Treatments Based on Cancer Vaccines: Combination with Checkpoint Inhibitors and Beyond.. <b>2022</b> ,	
223	Rationale and design of a prospective, multicenter, phase II clinical trial of safety and efficacy evaluation of long course neoadjuvant chemoradiotherapy plus tislelizumab followed by total mesorectal excision for locally advanced rectal cancer (NCRT-PD1-LARC trial).. <b>2022</b> , 22, 462	0
222	Exploring the educational needs for severe immune-related adverse events of PD-1/PD-L1 inhibitors in advanced lung cancer : A single-center observational study. <b>2022</b> , 100076	
221	The cure from within? a review of the microbiome and diet in melanoma.. <b>2022</b> ,	1
220	Combination of interventional oncology local therapies and immunotherapy for the treatment of hepatocellular carcinoma.	1
219	Avelumab First-Line Maintenance Treatment in Advanced Bladder Cancer: Practical Implementation Steps for Infusion Nurses.. <b>2022</b> , 45, 142-153	
218	Safety and potential increased risk of toxicity of radiotherapy combined immunotherapy strategy.. <b>2022</b> ,	1
217	Adverse and unconventional reactions related to immune checkpoint inhibitor therapy for cancer.. <b>2022</b> , 108, 108803	0
216	Severe immune checkpoint inhibitor-associated gastritis: A case series and literature review.	0
215	Treatment of patients with cancer using PD-1/PD-L1 antibodies: Adverse effects and management strategies (Review).. <b>2022</b> , 60,	0
214	Small cell lung cancer patients treated with immune checkpoint inhibitor: a systematic literature review of treatment efficacy, safety, and quality of life.. <b>2022</b> , 1-13	0
213	Efficacy and safety of bicyclol for treating patients with idiosyncratic acute drug-induced liver injury: A multicenter, randomized, phase II trial.. <b>2022</b> ,	
212	Mechanism and Management of Checkpoint Inhibitor-Related Toxicities in Genitourinary Cancers. <b>2022</b> , 14, 2460	
211	Update in TIGIT Immune-Checkpoint Role in Cancer. <b>2022</b> , 12,	1
210	Role of Abdominal and Pelvic CT Scans in Diagnosis of Patients with Immunotherapy-Induced Colitis. <b>2022</b> , 5, 32-36	0

209	Desarrollo e implementaci3n de una unidad de inmunoterapia en un servicio de urolog3a. <b>2022,</b>	
208	Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of lung cancer and mesothelioma. <b>2022, 10, e003956</b>	0
207	Celebrating a decade of the Journal for ImmunoTherapy of Cancer. <b>2022, 10, e005207</b>	
206	Adverse effects under immune checkpoint inhibitors on 18F-FDG PET/CT imaging.	0
205	Construction and Validation of a Tumor Microenvironment-Based Scoring System to Evaluate Prognosis and Response to Immune Checkpoint Inhibitor Therapy in Lung Adenocarcinoma Patients. <b>2022, 13, 951</b>	1
204	Identification of a Germline Pyrin Variant in a Metastatic Melanoma Patient With Multiple Spontaneous Regressions and Immune-related Adverse Events. <b>30, Publish Ahead of Print,</b>	0
203	Influenza Vaccination in Cancer Patients Treated With Immune Checkpoint Inhibitors: A Systematic Review and Meta-analysis. <b>1, Publish Ahead of Print,</b>	2
202	Immune-related adverse events in older adults: Data mining of the FDA Adverse Event Reporting System. <b>2022,</b>	0
201	Neoadjuvant Immunotherapy in Gastrointestinal Cancers [The New Standard of Care?. <b>2022,</b>	0
200	Thyroid cancer. <b>2023, 383-387</b>	
199	Plasma Exchange for Severe Immune-Related Adverse Events from Checkpoint Inhibitors: An Early Window of Opportunity?.	1
198	Metastatic Merkel carcinoma complicated by transverse myelitis during immuno-oncological therapy.	
197	Emerging Management Approach for the Adverse Events of Immunotherapy of Cancer. <b>2022, 27, 3798</b>	5
196	Clinical Manifestations, Monitoring, and Prognosis: A Review of Cardiotoxicity After Antitumor Strategy. <b>9,</b>	0
195	Challenging Dermatologic Considerations Associated with Immune Checkpoint Inhibitors.	0
194	Development of hepatitis triggered by SARS-CoV-2 vaccination in patient with cancer during immunotherapy: a case report.	1
193	Top Ten Tips Palliative Care Clinicians Should Know About Managing Immune-Mediated Endocrine Toxicities in Cancer.	
192	An Oncology Urgent Care Clinic for the Management of Immune-Related Adverse Events: A Descriptive Analysis. <b>2022, 29, 4342-4353</b>	

- 191 Pharmacological Treatments Available for Immune-Checkpoint-Inhibitor-Induced Colitis. **2022**, 10, 1334 ○
- 190 SHR-1701, a Bifunctional Fusion Protein Targeting PD-L1 and TGF $\beta$  for Recurrent or Metastatic Cervical Cancer: A Clinical Expansion Cohort of Phase I Study. OF1-OF9 ○
- 189 A Case of abdominal pain and diarrhea post immunotherapy: Hypophysitis associated with immune checkpoint inhibitors. **2022**, ○
- 188 Was muss der Internist bei Patienten unter Biologikabehandlung beachten?. ○
- 187 Contrasting autoimmune and treatment effects reveals baseline set points of immune toxicity following checkpoint inhibitor treatment. ○
- 186 Multi-organ Immune-Related Adverse Event Is a Risk Factor of Immune Checkpoint Inhibitor-Associated Myocarditis in Cancer Patients: A Multi-center Study. 13, ○
- 185 The Risk of Opportunistic Infections and the Role of Antibiotic Prophylaxis in Patients on Checkpoint Inhibitors Requiring Steroids. **2022**, 20, 800-807.e1 ○
- 184 The Meaning of Lymphadenopathies During Adjuvant Durvalumab After Chemoradiotherapy for Lung Cancer: Thinking Beyond Disease Progression. **2022**, ○
- 183 Real-world data analysis of immune checkpoint inhibitors in stage III-IV adenocarcinoma and squamous cell carcinoma. **2022**, 22, ○
- 182 A Profile of Avelumab Plus Axitinib in the Treatment of Renal Cell Carcinoma. Volume 18, 683-698 ○
- 181 Pneumopathie immuno-induite: un diagnostic différentiel de la pneumopathie  $\hat{S}$ ARS-CoV-2. **2022**, ○
- 180 Immune-related adverse events of cancer immunotherapies targeting kinases. **2022**, 108250 ○
- 179 Toxicity spectrum of immunotherapy in advanced lung cancer: A safety analysis from clinical trials and a pharmacovigilance system. **2022**, 50, 101535 ○
- 178 Musculoskeletal and Neurological Complications of Check Point Inhibitors. **2023**, 207-214 ○
- 177 Delayed immune-related sclerosing cholangitis after discontinuation of pembrolizumab: A case report. **2022**, 28, 3732-3738 ○
- 176 Checkpoint inhibitor-induced hepatotoxicity: Role of liver biopsy and management approach. **2022**, 14, 1269-1276 ○
- 175 Proposed clinical phases for the improvement of personalized treatment of checkpoint inhibitor-related pneumonitis. 13, ○
- 174 Pathophysiology of Cardiac Toxicity. **2022**, 31-43 ○

- 173 Imaging features of toxicities associated with immune checkpoint inhibitors. **2022**, 9, 100434 1
- 172 Immune Checkpoint Inhibitors Induced Hepatotoxicity; Gastroenterologists' Perspectives. **2022**, 14, 244-253
- 171 Neurologic adverse events of cancer immunotherapy. **2022**, 80, 270-280
- 170 Case Report: Successful treatment of late-onset immune checkpoint inhibitor-associated membranous nephropathy in a patient with advanced renal cell carcinoma. 13, 0
- 169 Renal Toxicities in Cancer Patients Receiving Immune-Checkpoint Inhibitors: A Meta-Analysis. **2022**, 11, 4373
- 168 Safety and Tolerability of MEDI0562, an OX40 Agonist mAb, in Combination with Durvalumab or Tremelimumab in Adult Patients with Advanced Solid Tumors. OF1-OF11 0
- 167 Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of nonmelanoma skin cancer. **2022**, 10, e004434 1
- 166 Immune checkpoint inhibitor-related pneumonitis in non-small cell lung cancer: A review. 12, 0
- 165 The association between antibiotic use and outcomes of HCC patients treated with immune checkpoint inhibitors. 13, 0
- 164 Focus on anticancer therapy-induced cardiotoxicity from the perspective of oncologists. Publish Ahead of Print, 0
- 163 Neural Net Modeling of Checkpoint Inhibitor Related Myocarditis and Steroid Response. Volume 14, 69-90
- 162 Immunogenic Cell Death Enhances Immunotherapy of Diffuse Intrinsic Pontine Glioma: From Preclinical to Clinical Studies. **2022**, 14, 1762 0
- 161 TNF- $\alpha$  inhibitor ameliorates immune-related arthritis and pneumonitis in humanized mice. 13, 1
- 160 Rationale and Clinical Research Progress on PD-1/PD-L1-Based Immunotherapy for Metastatic Triple-Negative Breast Cancer. **2022**, 23, 8878 0
- 159 Eosinophil as a biomarker for diagnosis, prediction, and prognosis evaluation of severe checkpoint inhibitor pneumonitis. 12, 0
- 158 Respiratory system toxicity induced by immune checkpoint inhibitors: A real-world study based on the FDA adverse event reporting system database. 12, 0
- 157 Mesalamine and cholestyramine for immune checkpoint inhibitor-mediated diarrhea and colitis.
- 156 Lenvatinib, toripalimab plus hepatic arterial infusion chemotherapy in patients with high-risk advanced hepatocellular carcinoma: A biomolecular exploratory, phase II trial. **2022**, 174, 68-77 2

- 155 Immune checkpoint inhibitor-associated arthritis in advanced pulmonary adenocarcinoma: A case report. **10**, 10701-10707 ○
- 154 An autopsy case of autoimmune meningoencephalitis caused by pembrolizumab. **2022**, 45, 102226 ○
- 153 Diagnostic Applications of Nuclear Medicine: Gastric Cancers. **2022**, 1-18 ○
- 152 Diagnostic Applications of Nuclear Medicine: Esophageal Cancers. **2022**, 1-18 ○
- 151 Pancreas and Gallbladder. **2022**, 255-264 ○
- 150 Hepatology (Liver and Bile Duct). **2022**, 119-165 ○
- 149 Magnetotherapy in patients with malignant tumors receiving immunotherapy. **2022**, 99, 51 ○
- 148 Supportivtherapie in der Uroonkologie. **2022**, 1-11 ○
- 147 Diagnostic Applications of Nuclear Medicine: Esophageal Cancers. **2022**, 811-828 ○
- 146 Rheumatology (Arthritis and Myositis). **2022**, 301-313 ○
- 145 Ophthalmology (Eye). **2022**, 231-253 ○
- 144 Dermatology (Skin). **2022**, 29-58 ○
- 143 Gastroenterology (GI). **2022**, 81-96 ○
- 142 Drug induced liver injury by immunotherapy. **2022**, ○
- 141 Management of Patients with Cardiac Toxicity: The Point of View of the Oncologist. **2022**, 91-111 ○
- 140 Cardiology (Heart). **2022**, 7-27 ○
- 139 Comprehensive rehabilitation of immune-mediated adverse events in cancer patients receiving checkpoint inhibitor therapy. **2022**, 99, 30 ○
- 138 Diagnostic Applications of Nuclear Medicine: Gastric Cancers. **2022**, 829-846 ○

137	Pulmonology (Lung). <b>2022</b> , 275-299	0
136	Immune-Related Uncommon Adverse Events in Patients with Cancer Treated with Immunotherapy. <b>2022</b> , 12, 2091	1
135	Cardiotoxicity of immune checkpoint inhibitors: A frequency network meta-analysis. 13,	0
134	Role of cytoreductive surgery in the era of immunotherapy. <b>2022</b> , 32, 618-626	1
133	Case report: Pneumonia with clinical symptoms precedes imaging evidence after immune checkpoint inhibitors combined with radiotherapy in lung squamous cell cancer. 13,	0
132	: A case report of re-challenge of immune checkpoint inhibitors after immune-related neurological adverse events: Review of literature. <b>2022</b> , 101, e30236	0
131	Immunotherapy-Associated Uveitis.	0
130	Cardiac Toxicity Associated with Immune Checkpoint Inhibitors: A Systematic Review. <b>2022</b> , 23, 10948	1
129	Endocrine-related adverse conditions in patients receiving immune checkpoint inhibition - an ESE clinical practice guideline. <b>2022</b> ,	3
128	Immune checkpoint inhibitor-induced hepatitis injury: risk factors, outcomes, and impact on survival.	0
127	Cardiotoxicity induced by immune checkpoint inhibitor: The complete insight into mechanisms, monitoring, diagnosis, and treatment. 9,	0
126	Thyroid Dysfunction in NonSmall Cell Lung Cancer With Immune Checkpoint Inhibitors: A Meta-Analysis.	0
125	Which cardiac parameters best predict the cardiovascular outcomes among patients with anti-PD-1 immunotherapy-induced myocardial injury?. 9,	0
124	Neurological adverse effects associated with anti-PD1 antibodies alone or in combination with ipilimumab: a multicenter case series. Publish Ahead of Print,	0
123	Incidence risk of peripheral edema in cancer patients treated with PD-1/PD-L1 inhibitors: A PRISMA guideline systematic review and meta-analysis. <b>2022</b> , 101, e30151	0
122	Distinct pre-treatment innate immune landscape and post-treatment T cell responses underlie immunotherapy-induced colitis.	0
121	Treatment of Brain Metastases: The Synergy of Radiotherapy and Immune Checkpoint Inhibitors. <b>2022</b> , 10, 2211	1
120	Pembrolizumab Administration Frequency, Dose Exposure, and Toxicity: Is Switching Safe?. <b>2022</b> , 17, 1155-1157	0



119	Consensus on the Key Characteristics of Immunotoxic Agents as a Basis for Hazard Identification. <b>2022</b> , 130,	2
118	Circulating biomarkers of response to immunotherapy and immune-related adverse events. 1-11	0
117	Drug-Induced Vasculitis. <b>2022</b> , 173-180	0
116	A Retrospective Cohort Study of Multiple Immune-Related Adverse Events and Clinical Outcomes Among Patients With Cancer Receiving Immune Checkpoint Inhibitors. <b>2022</b> , 29, 107327482211305	0
115	Cutaneous Reactions to Oncologic Immunotherapy. <b>2022</b> , 317-330	0
114	Identification of a novel necroptosis-associated miRNA signature for predicting the prognosis in head and neck squamous cell carcinoma. <b>2022</b> , 17, 1682-1698	0
113	Tratamiento del c�ncer de ri�n metast�sico. <b>2022</b> , 54, 1-13	0
112	Targeted Therapy and Immunotherapy in Melanoma. <b>2022</b> ,	2
111	Neurological adverse events of immune checkpoint blockade: from pathophysiology to treatment. Publish Ahead of Print,	0
110	Update on Immune Checkpoint Inhibitor Enterocolitis.	0
109	Oncologic Emergencies. 1-21	0
108	Imaging features of immune checkpoint inhibitor-related nephritis with clinical correlation: a retrospective series of biopsy-proven cases.	0
107	Immune Checkpoint inhibitor Enterocolitis vs Idiopathic Inflammatory Bowel Disease. <b>2022</b> ,	0
106	A Case Report of Immune Checkpoint Inhibitor-Induced Aortitis Treated with Tocilizumab. <b>2022</b> , 2022, 1-3	0
105	Immune checkpoint inhibitor related nephrotoxicity: Advances in clinicopathologic features, noninvasive approaches, and therapeutic strategy and rechallenge. 2,	0
104	Gastrointestinal and Hepatic Complications in Cancer Patients. 1-18	0
103	Cardiotoxicity Induced by Immune Checkpoint Inhibitors: What a Cardio-Oncology Team Should Know and Do. <b>2022</b> , 14, 5403	0
102	Immune checkpoint blockade in melanoma: Advantages, shortcomings and emerging roles of the nanoparticles. <b>2022</b> , 113, 109300	0

101	A Review of Immune Checkpoint Blockade for the General Surgeon. <b>2023</b> , 281, 289-298	0
100	Unlocking the Potential of Immuno-Oncology in Advanced Cutaneous Squamous Cell Carcinoma: Role of Checkpoint Blockade. 2-10	0
99	Unlocking the Potential of Immuno-Oncology in Advanced Cutaneous Squamous Cell Carcinoma: Role of Checkpoint Blockade. 2-10	0
98	Real-world landscape transition of death causes in the immunotherapy era for metastatic non-small cell lung cancer. 13,	0
97	Recomendaciones iniciales para el manejo de los eventos adversos más frecuentes de la inmunoterapia en el tratamiento del cáncer. <b>2022</b> , 24,	0
96	Differentiating Immune-Related Adrenal Insufficiency From Low Cardiac Output Syndrome: A Case Report. <b>2022</b> ,	0
95	A rapid review of patient-reported outcomes investigated in the context of advanced renal cell cancer or advanced hepatocellular cancer. <b>2022</b> , 102241	0
94	Deaths and adverse events from adjuvant therapy with immune checkpoint inhibitors in solid malignant tumors: A systematic review and network meta-analysis.	0
93	A Retrospective, Single-Institution Experience of Bullous Pemphigoid as an Adverse Effect of Immune Checkpoint Inhibitors. <b>2022</b> , 14, 5451	2
92	Activation of B cells in Tertiary Lymphoid Structures in cancer: Anti-tumor or anti-self?. <b>2023</b> , 65, 101703	0
91	Pacemakers and methylprednisolone pulse therapy in immune-related myocarditis concomitant with complete heart block. <b>2022</b> , 17, 2109-2116	1
90	Immunotherapy for Cancer: Common Gastrointestinal, Liver, and Pancreatic Side Effects and Their Management. <b>2022</b> , 117, 1917-1932	0
89	Multisystem immune-related adverse events due to toripalimab: Two cases-based review. 9,	1
88	Highlights on Ocular Toxicity of Immune Checkpoint Inhibitors at a US Tertiary Cancer Center. <b>2022</b> , 5, 98-104	0
87	Immunogenomic correlates of immune-related adverse events for anti-programmed cell death 1 therapy. 13,	0
86	Early increase of circulating transitional B cells and autoantibodies to joint-related proteins in patients with metastatic melanoma developing checkpoint inhibitor-induced inflammatory arthritis.	0
85	Development and implementation of an immunotherapy unit in a urology department. <b>2022</b> ,	0
84	Severe Gastritis Due to Nivolumab Treatment of a Metastatic Melanoma Patient. <b>2022</b> , 12, 2864	0

83	Home-based multidisciplinary interventions on skin adverse reactions in EGFR-TKI-treated patients with lung cancer: a protocol for a randomised controlled trial. <b>2022</b> , 12, e063921	0
82	Acetylcholine receptor binding antibody-associated myasthenia gravis, myocarditis, and rhabdomyolysis induced by tislelizumab in a patient with colon cancer: A case report and literature review. <b>12</b> ,	1
81	The difficulty in translating the preclinical success of combined TGF $\beta$ and immune checkpoint inhibition to clinical trial. <b>2022</b> , 86, 104380	1
80	Simultaneous development of pneumonitis and autoimmune diabetes secondary to immune checkpoint inhibitor treatment with durvalumab in an advanced small cell lung cancer patient: A case report. <b>2022</b> , 101, e32076	0
79	Multiple White Plaques in the Esophagus: A Possible Case of Esophageal Mucosal Alteration Associated With Immune-Related Adverse Events of Immune Checkpoint Inhibitors. <b>2022</b> ,	0
78	Avelumab-Induced Scleroderma in a Patient with Metastatic Squamous Cell Carcinoma of the Lung. <b>2022</b> , 2022, 1-3	0
77	Immune-related adverse events: A bibliometric analysis. <b>13</b> ,	0
76	Correlation between immune-related adverse events and treatment efficacy of anti-PD1 immunotherapy in patients with esophageal squamous cell carcinoma. <b>2022</b> , 25,	0
75	Toxicidad digestiva en los tratamientos oncológicos. Revisión bibliográfica. Influencia en el estado nutricional. <b>2022</b> ,	0
74	Prognostic Significance of the Severity of Immune-Related Adverse Events in Advanced Cancer Patients Treated with PD-1/PD-L1 Inhibitors: A Real-World Data Analysis.	0
73	Safety and short-term outcomes of laparoscopic surgery for advanced gastric cancer after neoadjuvant immunotherapy: A retrospective cohort study. <b>13</b> ,	0
72	Afecciones tóxicas y endocrinas musculares. <b>2022</b> , 55, 1-13	0
71	Severe neuromuscular immune-related adverse events of immune checkpoint inhibitors at national cancer center in Korea.	0
70	Immunotherapy Use Prior to Liver Transplant in Patients with Hepatocellular Carcinoma. <b>2022</b> , 29, 9813-9825	0
69	Unravelling the genetic links between Parkinson disease and lung cancer. <b>2023</b> ,	0
68	Pembrolizumab induced remission of recurrent and metastatic sinonasal squamous cell carcinoma after overcoming checkpoint-inhibitor pneumonitis: A case report and literature review.	0
67	Case Report: Serial changes of ocular complications related to immune checkpoint inhibitors pembrolizumab and nivolumab. <b>2</b> ,	0
66	A Case Report of Successful Treatment of Severe Immunotherapy-related Hepatitis in a Patient with advanced Lung Squamous-cell carcinoma.	0

65	Mechanisms and therapeutic strategies of immune checkpoint molecules and regulators in type 1 diabetes. 13,	1
64	Role of Clock Genes and Circadian Rhythm in Renal Cell Carcinoma: Recent Evidence and Therapeutic Consequences. <b>2023</b> , 15, 408	0
63	Application of Immune Checkpoint Inhibitors in Gynecological Cancers: What Do Gynecologists Need to Know before Using Immune Checkpoint Inhibitors?. <b>2023</b> , 24, 974	0
62	The Current status of steroid-refractory immune-checkpoint-inhibitor-related hepatotoxicity. <b>2023</b> , 28, 101619	1
61	Management of Endocrine and Metabolic Toxicities of Immune-Checkpoint Inhibitors: From Clinical Studies to a Real-Life Scenario. <b>2023</b> , 15, 246	0
60	Association of immune-related adverse events and efficacy in advanced non-small-cell lung cancer: a systematic review and meta-analysis.	0
59	[18F]FDG PET/CT Imaging in Cancer Treatment with Checkpoint Inhibitors. <b>2023</b> , 1-40	0
58	Duration of Immunotherapy in Non-Small Cell Lung Cancer Survivors: A Lifelong Commitment?. <b>2023</b> , 15, 689	0
57	Hypertransaminasemia in cancer patients receiving immunotherapy and immune-based combinations: the MOUSEION-05 study.	1
56	Diagnostic et traitement des complications neurologiques des immunothérapies anticancéreuses. <b>2023</b> ,	0
55	Association between PD -1 inhibitor-related adverse events and frailty assessed by frailty index in lung cancer patients.	0
54	Cardiovascular, Renal and Pulmonary Toxicity of Immune Checkpoint Inhibitors in Cancer: What the GP Should Know. <b>2023</b> , 112, 160-171	1
53	Management of immune-mediated toxicities and their implications in the outcomes of advanced kidney cancer. <b>2023</b> , 15, 397-400	0
52	Cardiotoxicity, Cardioprotection, and Prognosis in Survivors of Anticancer Treatment Undergoing Cardiac Surgery: Unmet Needs. <b>2023</b> , 15, 2224	0
51	Updated Immunotherapy for Gastric Cancer. <b>2023</b> , 12, 2636	0
50	Efficacy and safety of transurethral resection of bladder tumour combined with chemotherapy and immunotherapy in bladder-sparing therapy in patients with T1 high-grade or T2 bladder cancer: a protocol for a randomized controlled trial. <b>2023</b> , 23,	0
49	Management, risk factors and prognostic impact of checkpoint-inhibitor pneumonitis (CIP) in lung cancer: A multicenter observational analysis. <b>2023</b> , 179, 107184	0
48	Combined radiation- and immune checkpoint-inhibitor-induced pneumonitis: The challenge to predict and detect overlapping immune-related adverse effects from evolving laboratory biomarkers and clinical imaging. <b>2023</b> , 39, 100892	0

47	Hypertransaminasemia in metastatic renal cell carcinoma patients receiving immune-based combinations: a meta-analysis. <b>2023</b> , 15, 117-126	1
46	Research progress on mechanisms and predictive biomarkers for immune-related adverse events.	o
45	Monitoring and Modulating Diet and Gut Microbes to Enhance Response and Reduce Toxicity to Cancer Treatment. <b>2023</b> , 15, 777	o
44	Dearth of ICD Codes for Complications of Immune Checkpoint Inhibitors Impedes Clinical Care and Research. <b>2023</b> , 7,	o
43	Learning from the nexus of autoimmunity and cancer. <b>2023</b> , 56, 256-271	o
42	Advances in immune checkpoint inhibitors induced-cardiotoxicity. 14,	o
41	Endocrine Consequences Following Immune Checkpoint Inhibitors Therapy. <b>2023</b> , 1-32	o
40	Digestive toxicity in cancer treatments. Bibliographic review. Influence on nutritional status. <b>2023</b> , 70, 136-150	o
39	Management of the adverse effects of cancer immunotherapy with a focus on the gastrointestinal and hepatic systems. <b>2023</b> , 66, 112-115	o
38	Expert Consensus on the Diagnosis and Treatment of Anticancer Drug-Induced Interstitial Lung Disease. <b>2023</b> , 43, 1-12	o
37	Safety evaluation of immune checkpoint inhibitors combined with chemotherapy for the treatment of small cell lung cancer: A meta-analysis of randomized controlled trials. <b>2023</b> , 14, 1029-1035	o
36	An Immunological Perspective on the Mechanism of Drug Induced Liver Injury: Focused on Drugs for Treatment of Hepatocellular Carcinoma and Liver Transplantation. <b>2023</b> , 24, 5002	o
35	Immune checkpoint inhibitors related respiratory disorders in patients with lung cancer: A meta-analysis of randomized controlled trials. 14,	o
34	Eosinophil and IFN- $\gamma$ associated with immune-related adverse events as prognostic markers in patients with non-small cell lung cancer treated with immunotherapy. 14,	o
33	IFN- $\gamma$ is a central node of cancer immune equilibrium. <b>2023</b> , 42, 112219	o
32	Treatment and outcomes of immune checkpoint inhibitors-associated colitis/diarrhea: A systematic review and meta-analysis. <b>2023</b> ,	o
31	Predictive Biomarkers for Checkpoint Inhibitor Immune-Related Adverse Events. <b>2023</b> , 15, 1629	o
30	Programmed Cell Death Protein 1 Inhibitor-Mediated Peripheral Neuropathy. <b>2023</b> , 4, 100495	o

- 29 Immune-induced pneumonia in patients with advanced solid tumors treated with immunotherapy: a real-world assessment. **2023**, 19, 259-270 ○
- 28 Rheumatologic immune checkpoint inhibitor-related adverse events. **2023**, 35, 141-148 ○
- 27 Antibody Levels Were Not Correlated with Islet Function in Patients with Checkpoint Inhibitor-Related Diabetes. **2023**, 13, 3287-3297 ○
- 26 Immunotherapy Targeting PD-1/PD-L1 in Early-Stage Triple-Negative Breast Cancer. **2023**, 13, 526 ○
- 25 Assessment of Symptoms and Adverse Events Related to Immunotherapy in Patients With Cancer: An Integrative Review. **2023**, ○
- 24 Neurological adverse events of immune checkpoint inhibitors: An update of clinical presentations, diagnosis, and management. **2023**, ○
- 23 Acute rejection was observed in a combination therapy of CTLA-4 and PD-1 inhibitors before liver transplantation: A case report and literature review. **2023**, ○
- 22 Adverse events and clinical outcomes in patients treated with PD-(L)1 blockade for advanced non-small-cell lung cancer. **2022**, 18, 4509-4523 ○
- 21 Characterization of immunomodulatory factors and cells in bronchoalveolar lavage fluid for immune checkpoint inhibitor-related pneumonitis. ○
- 20 Immune checkpoint inhibitor-related thyroid dysfunction. **2023**, ○
- 19 Immune checkpoint inhibitor-induced autoimmune encephalitis in metastatic squamous cell lung cancer. **2023**, 15, 409-416 ○
- 18 Positron Emission Tomography-Based Immunoimaging for Cancer Patient Stratification: Toward a More Holistic Approach. ○
- 17 Clinicopathological classification of immune checkpoint inhibitor-associated myocarditis: possible refinement by measuring macrophage abundance. **2023**, 9, ○
- 16 Patterns of Response to Immune Oncology Drugs: How Relevant Are They in SCCHN?. **2023**, 217-228 ○
- 15 Toxicitatea cardiacă a inhibitorilor punctelor de control (IPC) utilizată în imunoterapia cancerului. **2023**, 1, 23 ○
- 14 Identification and Characterisation of Infiltrating Immune Cells in Malignant Pleural Mesothelioma Using Spatial Transcriptomics. **2023**, 6, 35 ○
- 13 Sicca symptoms and sialoadenitis as immune-related adverse events of nivolumab treatment in renal malignancy. **2023**, 13, 21-23 ○
- 12 Hydrogel-enabled, local administration and combinatorial delivery of immunotherapies for cancer treatment. **2023**, ○

- 11 Immune-related pulmonary toxicities of checkpoint inhibitors in non-small cell lung cancer: Diagnosis, mechanism, and treatment strategies. 14, ○
- 10 75-Year-Old Woman With Deranged Liver Enzymes. **2023**, ○
- 9 Multidisciplinary recommendations for essential baseline functional and laboratory tests to facilitate early diagnosis and management of immune-related adverse events among cancer patients. ○
- 8 Head and neck cancer treatment in the era of molecular medicine. **2023**, ○
- 7 Real-world clinical outcomes of nivolumab and taxane as a second- or later-line therapy for recurrent or unresectable advanced esophageal squamous cell carcinoma. 13, ○
- 6 Gastrointestinal injury induced by immunomodulators: A review article. **2023**, 16, 175628482311585 ○
- 5 Correlation of preclinical and clinical biomarkers with efficacy and toxicity of cancer immunotherapy. **2023**, 15, 175883592311638 ○
- 4 Added diagnostic value of routinely measured hematology variables in diagnosing immune checkpoint inhibitor mediated toxicity in the emergency department. ○
- 3 Extensive CARdioVAscular Characterization and Follow-Up of Patients Receiving Immune Checkpoint Inhibitors: A Prospective Multicenter Study. **2023**, 16, 625 ○
- 2 Research Hotspot and Application Status of Immune Evasion Mechanism in Ovarian Cancer. **2023**, 11, 443-455 ○
- 1 Gastrointestinal treatment-related adverse events of combined immune checkpoint inhibitors: a meta-analysis. ○